Helicobacter pyloriと胃粘膜病変〈最新の研究成果〉第2版

出版社： 先端医学社
著者：
発行日： 1999-09-20
分野： 臨床医学：内科  >  胃/腸
ISBN： 9784915892844
電子書籍版： 1999-09-20 （第2版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,575 円(税込)

購入する

商品紹介

年々活発となるHelicobacter pyloriの研究成果を解説。1995年の初版以来、蓄積したデータを加え第2版として刊行。H. pyloriの教科書として高い評価を受けた本書第1版を受けて、第2版では最新の研究成果に加え、第1版では記載しにくかった重要論点10項を選び、最前線の知見を解説。H. pylori研究にかかわる方々のための座右の書。

目次

  • 表紙
  • 第2版 序
  • 序
  • 執筆者一覧
  • CONTENTS
  • 第1章 座談会 「Helicobacter pylori研究はどこまで進歩したのか」
  • 第2章 細菌学的特徴
  • はじめに
  • 1 歴史と分類
  • 2 形態・生化学性状と培養
  • 3 染色体 ( 遺伝子 ) 蛋白の特徴
  • 4 菌の特徴と病原性との関係
  • [1] 酸耐性性と侵入・定着
  • [2] 細胞傷害・発症
  • おわりに
  • 第3章 疫学
  • はじめに
  • 1 疫学調査におけるHelicobacter pylori感染の診断方法
  • 2 感染経路の疫学的研究
  • 3 無症候者におけるHelicobacter pyloriの疫学
  • [1] 先進国と発展途上国
  • [2] わが国における感染率
  • 4 Helicobacter pylori感染に影響を及ぼす要因 - 小児期における環境の重要性 -
  • 5 Helicobacter pyloriの罹患率
  • おわりに
  • 第4章 細胞傷害機序
  • はじめに
  • 1 Helicobacter pyloriの運動性と付着
  • 2 細胞傷害機序
  • [1] アンモニアが関連する傷害
  • [2] 空胞化サイトトキシンによる傷害
  • [3] 浸潤炎症細胞による傷害
  • おわりに
  • 第5章 動物モデル
  • はじめに
  • 1 霊長類
  • 2 マウス
  • 3 スナネズミ
  • 4 無菌ミニブタ
  • 5 その他
  • おわりに
  • 第6章 疾患とのかかわり
  • (1) 胃炎
  • はじめに
  • 1 胃炎の概念と診断の変遷
  • 2 胃炎の分類
  • 3 Helicobacter pylori感染と胃炎の多様性
  • 4 Helicobacter pyloriの除菌により胃粘膜萎縮は改善するか
  • おわりに
  • (2) 消化性潰瘍
  • A : 胃潰瘍
  • はじめに
  • 1 感染実験における潰瘍発生とHelicobacter pyloriの関連
  • 2 胃潰瘍におけるHelicobacter pylori検出率
  • 3 Helicobacter pyloriの胃内分布と潰瘍発症
  • 4 Helicobacter pyloriの病原性と潰瘍
  • 5 潰瘍治癒とHelicobacter pylori
  • 6 遺伝的素因とHelicobacter pylori
  • 7 酸分泌とHelicobacter pyloriの関連
  • 8 Helicobacter pyloriの除菌治療
  • おわりに
  • B : 十二指腸潰瘍
  • はじめに
  • 1 十二指腸潰瘍とHelicobacter pyloriの歴史
  • [1] 診断ミス
  • [2] 環境因子
  • [3] 菌株
  • [4] 感染経路と重感染
  • [5] 感染時期説
  • 2 胃酸分泌とガストリン
  • 3 慢性胃炎
  • 4 胃上皮化生
  • おわりに
  • C : 小児消化性潰瘍
  • はじめに
  • 1 Helicobacter pylori感染と胃炎
  • 2 十二指腸潰瘍
  • 3 胃潰瘍
  • 4 Helicobacter pylori陽性潰瘍の治療
  • (3) 胃癌
  • はじめに
  • 1 Helicobacter pylori持続感染による萎縮性胃炎および腸上皮化生への進展
  • 2 Helicobacter pylori感染 - 胃炎から胃癌へ -
  • おわりに
  • (4) 胃リンパ腫
  • はじめに
  • 1 Helicobacter pylori除菌による変化
  • [1] 対象および方法
  • [2] 結果
  • 2 胃悪性リンパ腫切除例の検討
  • [1] 対象および方法
  • [2] 結果
  • 3 考察
  • おわりに
  • (5) 胃食道逆流症
  • はじめに
  • 1 疫学的関連について
  • 2 攻撃的因子としてのHelicobacter pylori
  • 3 保護的因子としてのHelicobacter pylori
  • 4 Helicobacter pyloriと維持療法
  • 5 Helicobacter pylori感染からみた胃食道逆流症の今後
  • おわりに
  • (6) 消化管以外の疾患
  • 1 Helicobacter pylori感染と虚血性心疾患
  • 2 Helicobacter pylori感染と発育障害
  • 3 Helicobacter pylori感染と皮膚科疾患
  • 4 Helicobacter pylori感染と肝性脳症
  • 5 Helicobacter hepaticusによるマウスの肝病変
  • 6 Helicobacter pyloriと口腔内疾患
  • 7 Helicobacter pylori感染とそのほかの疾患
  • 第7章 診断
  • (1) 総論
  • はじめに
  • 1 内視鏡検査を必要とする診断法
  • [1] ラピッドウレアーゼテスト ( 迅速ウレアーゼ試験 )
  • [2] 組織鏡検法
  • [3] 培養法
  • [4] 遺伝子診断
  • [5] 色素散布法
  • 2 内視鏡検査を必要としない方法
  • [1] 血中抗Helicobacter pylori IgG抗体
  • [2] 13C - ウレアブレステスト ( 13C - 尿素呼気試験 )
  • おわりに
  • (2) 血清診断
  • はじめに
  • 1 血清抗Helicobacter pylori抗体検出キット
  • 2 今後の抗Helicobacter pylori IgG抗体の測定
  • 3 血清抗Helicobacter pylori IgG抗体測定の意義
  • 4 その他の抗体測定
  • おわりに
  • (3) ラピッドウレアーゼテスト
  • はじめに
  • 1 ラピッドウレアーゼテスト
  • [1] 原理
  • [2] 実際の検査方法と偽陰性, 偽陽性の問題
  • [3] 市販ラピッドウレアーゼテストの有用性
  • 2 色素散布法
  • 3 胃粘液のウレアーゼ測定
  • おわりに
  • (4) ポリメラーゼ連鎖反応法
  • はじめに
  • 1 ポリメラーゼ連鎖反応法によるHelicobacter pyloriの検出例
  • 2 プライマーと検出効率
  • (5) 培養法
  • はじめに
  • 1 Helicobacter pylori培養法の実際
  • [1] 検体採取
  • [2] 検体の輸送
  • [3] Helicobacter pyloriの分離
  • [4] Helicobacter pyloriの保存
  • 2 Helicobacter pyloriの同定
  • 3 培養法の成績
  • 4 除菌療法と培養法
  • おわりに
  • (6) 鏡検法
  • はじめに
  • 1 Helicobacter pylori感染胃粘膜の病理組織所見
  • [1] 炎症性細胞浸潤, とくに好中球浸潤
  • [2] 上皮細胞の変化
  • [3] Helicobacter pyloriの存在部位
  • 2 Helicobacter pyloriの染色法
  • [1] H & E染色
  • [2] Giemsa染色変法
  • [3] Warthin - Starry変法
  • [4] Steiner - Steiner変法
  • [5] Gimenez染色変法
  • [6] Acridine - orange染色
  • [7] 免疫染色法
  • [8] in situ hybridization ( ISH ) 法
  • おわりに
  • (7) 13C - ウレアブレステスト
  • はじめに
  • 1 13C - ウレアブレステストの原理
  • 2 13C - ウレアブレステストの利点
  • 3 13C - ウレアブレステストの実際
  • 4 13C - ウレアブレステストの従来の診断法との比較
  • 5 13C - ウレアブレステストの問題点
  • おわりに
  • 第8章 治療
  • (1) 除菌の適応疾患
  • はじめに
  • 1 除菌療法の実施を強く勧告するもの
  • [1] 消化性潰瘍
  • [2] 胃MALToma ( 悪性リンパ腫 )
  • [3] 早期胃癌切除後
  • [4] 高度胃炎
  • 2 除菌療法の実施を推奨するもの
  • 3 除菌適応における今後の課題
  • おわりに
  • (2) 除菌療法の実際
  • はじめに
  • 1 Helicobacter pylori感染症の治療適応
  • 2 Helicobacter pylori除菌治療の変遷
  • 3 除菌治療におけるプロトンポンプ・インヒビターの役割
  • 4 耐性菌への除菌治療
  • おわりに
  • (3) 各論
  • A : PPI
  • 1) オメプラゾール
  • はじめに
  • 1 オメプラゾールの薬理作用
  • 2 オメプラゾールを用いた除菌療法
  • [1] オメプラゾール単独療法
  • [2] オメプラゾールとアモキシシリン2薬併用療法
  • [3] オメプラゾールとクラリスロマイシンの2薬併用療法
  • [4] オメプラゾール + 抗菌薬2薬の3薬併用療法
  • おわりに
  • 2) ランソプラゾール
  • はじめに
  • 1 in vitroにおけるHelicobacter pyloriに対する作用
  • 2 臨床面からの評価
  • [1] アモキシシリンとの併用効果
  • [2] アモキシシリン + クラリスロマイシンとの併用効果
  • [3] mono, dual, triple therapyにおける除菌率
  • [4] ランソプラゾールを含むtriple therapyにおける除菌期間による除菌率の検討
  • 3 Helicobacter pylori除菌に対するランソプラゾールを用いた第2相試験
  • [1] 細菌学的効果 ( 第1次試験 )
  • [2] 細菌学的効果 ( 第2次試験 )
  • [3] 安全性
  • 4 世界でのHelicobacter pylori除菌療法に対する承認状況
  • 5 ランソプラゾールによる抗炎症作用
  • 3) ラベプラゾール
  • はじめに
  • 1 ラベプラゾールの抗Helicobacter pylori作用
  • 2 ラベプラゾールの抗Helicobacter pylori作用発現機序解明の試み
  • 3 ラベプラゾールによるHelicobacter pylori除菌療法
  • おわりに
  • B : 抗生物質, 抗原虫剤
  • 1) クラリスロマイシン
  • はじめに
  • 1 クラリスロマイシンの位置付け
  • 2 クラリスロマイシンの問題点と対策
  • 3 防御因子増強薬の併用療法
  • おわりに
  • 2) アモキシシリン
  • はじめに
  • 1 生物学的特徴
  • 2 胃内における作用機序
  • 3 プロトンポンプ・インヒビターとの併用による除菌成績
  • 4 除菌に伴う副作用
  • おわりに
  • 3) メトロニダゾール
  • はじめに
  • 1 メトロニダゾールの概要
  • 2 新3薬併用療法の除菌率とメトロニダゾール
  • 3 メトロニダゾールの副作用
  • 4 メトロニダゾール耐性菌
  • 5 Helicobacter pylori感染の治療ワークショップ
  • おわりに
  • C : 防御因子増強薬
  • 1) プラウノトール
  • はじめに
  • 1 プラウノトールとその代謝物での抗Helicobacter pylori作用
  • 2 プラウノトールのHelicobacter pylori細胞膜の透過性と流動性に対する影響
  • 3 in vitroでの耐性菌分離の試み
  • おわりに
  • 2) レバミピド
  • はじめに
  • 1 Helicobacter pylori接着にもとづく胃粘膜上皮細胞からのIL - 8産生誘導と遺伝子転写制御におけるNF - κBの役割 - レバミピドの作用点 -
  • 2 各種炎症性サイトカイン産生に対するレバミピドの効果
  • 3 IFN - γによる単核球・マクロファージ活性化における誘導型NO合成酵素 ( iNOS ) の発現とレバミピドの抑制効果
  • おわりに
  • 3) エカベトナトリウム
  • はじめに
  • 1 基礎
  • [1] Helicobacter pylori棲息部位とエカベトナトリウムの分布
  • [2] ウレアーゼ阻害作用
  • [3] 殺菌作用
  • [4] 殺菌作用のメカニズム
  • [5] 耐性菌に対する殺菌作用
  • [6] コッコイド型に対する殺菌作用
  • [7] 感染阻止作用
  • 2 臨床
  • [1] 臨床におけるエカベトナトリウムの上乗せ除菌効果
  • [2] 耐性問題に対して
  • おわりに
  • 4) スクラルファート
  • はじめに
  • 1 スクラルファートによるHelicobacter pylori除菌効果臨床試験成績
  • 2 スクラルファートによる臨床除菌効果の裏付け
  • [1] Helicobacter pyloriコロニー密度減少作用
  • [2] Helicobacter pyloriウレアーゼ活性抑制作用
  • [3] Helicobacter pyloriの粘膜上皮への付着に対する作用
  • [4] 抗生剤のHelicobacter pyloriに対する抗菌活性に及ぼす影響
  • [5] 抗生剤の胃粘膜付着増強作用
  • [6] Helicobacter pylori産生空胞化毒素抑制作用
  • [7] Helicobacter pyloriによる粘液防御機構破綻に対する作用
  • おわりに
  • 5) ポラプレジンク
  • はじめに
  • 1 Helicobacter pyloriの増殖に対する作用
  • 2 ウレアーゼ活性阻害作用
  • 3 起炎反応に対する作用
  • 4 Helicobacter pylori起因性胃粘膜炎症に対する作用
  • 5 ポラプレジンクを用いたHelicobacter pylori除菌療法
  • おわりに
  • D : その他
  • 1) ラニチジンビスマス
  • はじめに
  • 1 ラニチジンビスマスの特性
  • 2 ラニチジンビスマスのHelicobacter pylori除菌効果についての新しい話題
  • おわりに
  • 第9章 Helicobacter pylori研究におけるピットホール
  • 1. Helicobacter pylori除菌とH2受容体拮抗薬の維持療法 : どちらが再発予防に有効か ?
  • 2. Helicobacter pylori感染は, 急性胃粘膜病変の主要な原因か ?
  • 3. Helicobacter pylori感染により, 胃酸分泌は増えるのか ?
  • 4. Helicobacter pylori陰性潰瘍は, きわめてまれなのか ?
  • 5. Helicobacter pylori除菌療法における耐性菌の出現頻度は ?
  • 6. Helicobacter pylori感染は, NSAIDs由来胃病変形成にかかわっているか ?
  • 7. Helicobacter pylori感染がなければ, 胃粘膜萎縮や腸上皮化生は発生しないか ?
  • 8. Helicobacter pyloriの菌種の差より, 宿主の免疫反応のほうが胃粘膜傷害にとって重要か ?
  • 9. Helicobacter pyloriの感染源として内視鏡は重要か ?
  • 10. Helicobacter pyloriが常在菌である可能性はないのか ?
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第2章 細菌学的特徴

P.41 掲載の参考文献
1) Jean FT et al : The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 : 539-547, 1997
 
2) Kasai K et al : The stomach spirochete occurring in mammals. J, Parasitol 6 : 1-11, 1920
 
3) Appelmelk BJ et al : Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun 64 : 2031-2040, 1996
PubMed
4) Hirai Y et al : Unique cholesteryl glucosides in Helicobacter pylori : composition and structural analysis. J Bacteriol 177 : 5327-5333, 1995
PubMed
5) Haque M et al : Sterylglycosides : acharacteristic feature of the Helicobacter spp? J Bacteriol 177 : 5334- 5337, 1995
 
6) Haque M et al : Lipid profile of, Helicobacter spp : presence of cholesteryl glucoside as a characteristic feature. J Bacteriol 178 : 2065-2070, 1996
PubMed
7) John CA et al : Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. J Biol Chem 270 : 17771-17777, 1995
 
8) Emanuele P et al : The small GTP binding protein rab7 is essential for cellular vacuolation induced by Helicobacter pylori cytotoxin. EMBO J 16 : 15-24, 1997
 
9) Maurizio M et al : Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VagA. J Exp Med 187 : 135-140, 1998
 
10) Yahiro K et al : Helicobacter pylori vacuolating cytotoxin binds to the 140-kDa protein in human gastric cancer cell lines, AZ-521 and AGS. Biochem Biophys Res Commzan 238 : 629-632, 1997
 
11) Censini S et al : cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and diseaseassciated virulence factors. Proc Natl Acad Sci USA 93 : 14648-14653, 1996
PubMed
12) Yokota K et al : Heat shock protein produced by, Helicobacter pylori. Microbiol Immunol 38 : 403-405, 1994
PubMed
13) Kobayashi K et al : Detection of the heat shock protein on the follicular dendritic cells in the germinal centres of low grade B cell gastric lymphoma of mucosaassociated lymphoid tissue (MALT) type. J Clin Pathol 51 : 396-398, 1998
 
14) Kawahara et al : Antibodies to human gastric epithelial cells and heat shock protein in Helicobacter pylori-positive mucosa-associated lymphoid tissue lymphoma. Gut 45 : 20-23, 1999
PubMed
15) Yokota K et al : Gastric ulcers induced in severe combined immunodeficient mice by oral injection of Helicobacter pylori after transplanting lymphocytes from patients with MALToma. Gastroenterol (in press)
 

第3章 疫学

P.52 掲載の参考文献
1) Warren JR et al : Unidentified curved bacili on gastric epithelium in active chronic gastritis. Lancet i : 1273-1275, 1983
 
2) 加藤元嗣ほか : 消化性潰瘍とH. Pylori・セミナー/病態生理除菌判定 : 13C-尿素呼気試験. Med Pract 13 : 1871-1874, 1996
 
3) Talley NJ et al : Campylobacter pylori and Barret's esophagus Mayo Clin, Proc 63 : 1176-1180, 1988
 
4) Morris A et al : Campylobacter pylori infection in Mecker sdiverticula containing gastric mucosa. Gut 30 : 233, 1989
 
5) Dye KR et al : Campylobacter pylori colonizing heterotopic gastric tissue in the rectum. Am J Clin, Pathol 93 : 144-147, 1990
PubMed
6) Morris A et al : Ingestion of Campylobacter pylori dis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 : 192-199, 1987
 
7) Nguyen AH et at : Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction. J Clin Microbiol 31 : 763-787, 1993
 
8) Banatvala N et al : Helicobacter pylori in dental plaque. Lancet 341 : 380, 1993
PubMed
9) Shimada T et al : Identification of Helicobacter pylori in gastric specimens, gastric juice, saliva, and feces of Japanese patients. Lancet 343 : 1636-1637, 1994
PubMed
10) Li C et al : A newly developed PCR assay of H. pylori in gastric biopsy, saliva and feces. Dig, Dis Sci 41 : 2142- 2149, 1996
 
11) Mitchell HM et al : Increased incidence of Campylobacter pylori infection in gastroenterologists : further evidence of support person-to-person transmission of C. pylori. Scand J Gastroenterol 24 : 396-400, 1989
PubMed
12) Liu WZ et al : Seroprevalence of Helicobacter pylori Infection in Medical Staff in Shanghai. Scand J Gastroenterol 31 : 746-752, 1996
 
13) Hazell SL et al : Hepatitis A and evidence against the community dissemination of Helicobacter pylori via feces. J Infect Dis 170 : 686-689, 1994
PubMed
14) Drumm B et al : Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 322 : 359-363, 1990
PubMed
15) Malaty HM et al : Transmission of Helicobacter pylori infection. Studies in families of healthy individuals. Scand J Gastroenterol 26 : 927-932, 1991
PubMed
16) Bamfold K et al : H. pylori : comparison of DNA fingerprints provides evidence for intrafamilial infection. Gut 34 : 1348-1350, 1993
 
17) Axon AT : Is, Helicobacter pylori transmitted by the gastro-oral rout? Aliment Pharmacol Ther 9 : 585-588, 1995
 
18) Thomas JE et al : Isolation of Helicobacter pylori from human feces. Lancet 340 : 1194-1195, 1992
PubMed
19) Kelly SM et al : Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom Gastroenterology 107 : 1671-1674, 1994
PubMed
20) Megraud F : Transmission of Helicobacter pylori : faecal-oral versus oral-oral route. Aliment Pharmacol Ther 9 (suppl.) 2 : 85-91, 1995
 
21) Sahay P et al : Isolation of Helicobacter pylori from feces. J Infect 30 : 262-263, 1995
PubMed
22) Sahay P et al : Reservoirs of Helicobacter pylori and mode of transmission. Helicobacter 3 : 175-182, 1996
 
23) Klein PD et al : Water sourse as a risk factor for Helicobacter pylori infection in Peruvian children. Lancet, 337 : 1503-1506, 1991
 
24) Hulten K et al : Helicobacter pylori in the Drinking Water in Peru. Gastroenterology 110 : 1031-1035, 1996
PubMed
25) Hopkins RJ et al : Seroprevalence of Helicobacter pylori in Chile : Vegetablesmay serve as one route of transmission. J Infect Dis 168 : 222-226, 1993
PubMed
26) Handt LK et al : Characterization of feline Helicobacter pylori strains and associated gastritis in a colony of domestic cats. J Clin Microbiol 33 : 2280-2289, 1995
 
27) Grubel P et al : Vector potential of housefiies (Musca domestica) for Helicobacter pylori. J Clin Microbiol 35 : 1300-1303, 1997
PubMed
28) Sugiyama T et al : Is Helicobacter pylori infection responsible for postendoscopic acute gastric mucosal lesions? Eur J Gastroenterol Hepatol 4 (suppl. 1) : S93-96, 1992
 
29) Langenberg W et al : Patient-to-patient transmission of Campylobacter pylori infection by fiberoptic astroduodenoscopy and biopsy. J Infect Dis 161 : 507-511, 1990
PubMed
30) Megraud F : Epidemiology of Helicobacter pylori infection. Helicobacter pylori and gastroduodenal disease, ed. by Rathbone BJ et al, Blackwell Scientific publifications, London, 1992, pp. 107-123
 
31) Asaka M et al : Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102 : 760-766, 1992
 
32) Granstorm M et al : Seroepidemiology or Helicobacter pylori infection in a cohort of children monitoredfrom 6 months to 11 years of age. J Clin Microbiol 35 : 468-470, 1997
 
33) Goodman KJ et al : Helicobacter pylori infection in the Colombian Andes : apopulation-based study of transmission pathways. Am J Epidemiol 144 : 290-299, 1996
 
34) Klein PD et al : The epidemiology of Helicobacter pylori in Peruvian children between 6 and 30 months of age. Am J Gastroenterol 89 : 2196-2200, 1994
PubMed
35) Cave DR : How is Helicobacter pylori transmitted? Gastroenterology 113 : S9-S14, 1997
 
36) Graham DY et al : Epidemiology of Helicobacter pylori in an symptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100 : 1495-1501, 1991
 
37) Malaty HM et al : Importance of childhood socioeconomic status on the current prevalance of Helicobacter pylori infection. Gut 35 : 742-745, 1994
 
38) Marshall BJ et al : Attempt to fulkfil Koch's postulates for pylori c Campylobacter. Med J Aust 142 : 436-439, 1985
 
39) Morris A et al : Long-term follow-up of voluntary ingeg. tion of Helicobacter pylori. Ann Intern Med 114 : 662-664, 1991
 
40) Parsonnet J et al : Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 102 : 41-46, 1992
 
41) Rautelin H et al :, Helicobαcterpylori antibodies in students. Rev Esp Enferm Dig 78 (suppl. 1) : 34, 1990
 
42) Kosunen TU et al : Lrelicebαcter antibodies in 1973 and 1994 in the adult population of Vammala, Finland, Epidemiol Infect 119 : 29-34, 1997
 

第4章 細胞傷害機序

P.66 掲載の参考文献
1) Tomb JF et al : The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 : 539-547, 1997
PubMed
2) Mizote T et al : Urease-independent chemotactic responses of Helicobacter Pylori to urea, urerase inhibitors, and sodium bicarbonate. Infect Immun 65 : 1519-1521, 1997
PubMed
3) Kamisago S et al : Role of sulfatides in adhesion of. Helicobacter pylori to gastric cancer cells. Infect Immun 64 : 624-628, 1996
PubMed
4) Boren T et al : Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 262 : 1892-1895, 1993
PubMed
5) Yamaguchi H et al : Flowcytometric analysis of the heat shock protein 60 expressed on the cell surface of Helicobacter pylori. J Med Microbiol 45 : 270-277, 1996
 
6) Wagner S et al : Regulation of Gastric Epithelial Cell Growth by Helicobacter pylori : Evidence for a Major Role of Apoptosis. Gastroenterology 113, 1836-1847, 1997
 
7) Suzuki M et al : Helicobacter pylori -associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. Am J Physiol 263 : G719-G725, 1992
PubMed
8) Schimit W et al : Genetic analysis of the Helicobaeter pylori vacuolating cytotoxin : structural similarities with the IgA protease type of exported protein. Mol Microbiol 12 : 307-319, 1994
 
9) Atherton JC et al : Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori : association of specific vacA types with cytotoxin production and peptic ulceration. J Biolohem 270 : 17771-17777, 1995
PubMed
10) Harris PR et al : Helicobacter pylori Cytotoxin lnduces Vacuolation of Primary Human Mucosal Epithelial Cells. Infect Immun 64 : 4867-4871, 1996
 
11) Garner JA et al : Binding and Internalization of the Helicobacter pylori vacuolating cytotoxin by epitherial cells. Infect Immun 64 : 4197-4203, 1996
 
12) Bernard M et al : Identification of the Helicobacter Pylori VacA Toxin Domain Active in the Cell Cytosol. Infect Immun 66 : 6014-6016, 1998
PubMed
13) Yahiro K et al : Helicobacter pylori Vatuolating cytotoxin (VacA) binds to the 140kDa protein in human gastric cancer cell lines, AZ-521 and AGS. Biochem Biophys Res Commun 238 : 629-632, 1997
 
14) Tummuru MKR et al : Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol 18 : 867-876, 1995
 
15) Glocker E et al : Proteins Encoded by the cag Pathogenicity Island of, Helicobacter Pylori Are Required for NF-kB Activation. Infect Immune 66 : 2346-2348, 1998
 
16) Censini S et al : cag, a pathogenicity island of Helicobacter pylori, encodes type 1-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 93 : 14648-14653, 1996
 
17) Maeda S et al : High Seropositivity of Anti-CagA Antibody in Helicobacter pylori -Infected Patients Irrelevant to Peptic Ulcers and Normal Mucosa in Japan. Dig Dis Sci 42 : 1841-1847, 1997
PubMed
18) ELios MM et al : T Helper 1 Effector Cells Specific for Helicobacter Pylori in the Gastric Antrum of Patients with Peptic Ulcer Disease. J Immunol 158 : 962-967, 1997
PubMed
19) 大原正志 : 宿主免疫よりみた胃粘膜傷害の機序. G. I. Res 4 : 668-674, 1996
Medical*Online
20) Appelmelk BJ et al : Potential Role of Molecular Mimicry between Helicobacter pylori Lipopolysaccharide and Host Lewis Blood Group Antigens in Autoimmunity. Infect Immune 64 : 2031-2040, 1996
 

第5章 動物モデル

P.77 掲載の参考文献
1) Correa P : Human gastric carcinogenesis : a multistep and mutifactorial process-first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52 : 6735-6740, 1992
 
2) Parsonnet J et al : Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330 : 1267-1271, 1994
PubMed
3) Marshall BJ et al : Attempt to fulfill Koch's postulates for pylori Campylobacter. Med J Aust 142 : 436-439, 1985
 
4) Marchetti M et al : Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 262 : 1655-1658, 1995
 
5) Krakowka S et al : Establishment of gastric Campylobacter pylori infection in the neonatal gnotobiotic piglet. Infect Immun 55 : 2789-2796, 1987
PubMed
6) Lambert JR et al : Colonization of gnotobiotic piglets with Campylobacter pylori dis-an animal model?. J Infect Dis 155 : 1344, 1987
 
7) Radin MJ et al : Helicobacter pylori gastric infection in grtotobiotic beagle dogs. Infect Immun 58 : 2606-2612, 1990
PubMed
8) Karita M et al : New small animal model for human gastric Helicobacter pylori infection : success in both nude and euthymic mice. Am J Gastroenterol 86 : 1596-1603, 1992
 
9) 中野正美 : Campylobacter pyloriと胃炎・胃潰瘍-定量法による実験的および臨床的研究-. 杏林医学会雑誌 20 : 349-355, 1990
 
10) Euler AR et al : Evaluation of two monkey species (Macaca mulatta and Macaca fascicularis) as possible models for human Helicobacter pylori disease. J Clin Microbiol 28 : 2285-2290, 1990
 
11) Shuto R et al : Experimental gastritis induced by Helicobacter pylori in Japanese Monkeys. Infect Immun 61 : 933-939, 1993
PubMed
12) Yokota K et al : Colonization of Helicobacter pylori in the gastric mucosa of Mongolian gerbils. Microbiol Immunol 35 : 475-480, 1991
PubMed
13) Hirayama F et al : Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J Gastroenterol 31 : 755-757, 1996
PubMed
14) Curry A et al : Spiral organisms in the baboon stomach. Lancet 2 : 634-635, 1987
PubMed
15) Matsumoto S : Induction of ulceration and severe gastritis in Mongolian gerbil by Heticobacter pylori infection. J Med Microbiol 46 : 391-397, 1997
PubMed
16) Lee A et al : A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 99 : 1315-1323, 1990
 
17) Radclff FJ et al : Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 65 : 4668-4674, 1997
 
18) Sakagami T et al : Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 39 : 639-648, 1996
PubMed
19) Enno A et al : MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma. Am J Pathol 147 : 217-222, 1995
PubMed
20) Cellini L et al : Coccoid Helicobacter pylori not culturable in vitro reverts in mice. Microbiol Immunol 38 : 843-850, 1994
 
21) 清水伸幸ら : 障害胃粘膜に対するHelicobacter pylori感染-小動物による実験的考察-. DDW-Japan 1997, 消胃 p. 98, 1997
 
22) Lee A et al : A Standardized mouse model of Helicobacter pylori infection : introducing the Sydney strain. Gastroenterology 112 : 1386-1397, 1997
 
23) 平山文博ら : スナネズミH. Pylori感染モデルにおける基礎的検討, 第25回日本実験潰瘍学会 (東京), W1, 1997
 
24) 杉山敦ら : Helicobacter Pylori長期感染モデルの組織像の検討-胃粘膜過形成所見について-. 第25回日本実験潰瘍学会 (東京), No. 52, 1997
 
25) 山本昌美ら : MNUならびにMNNGによるスナネズミ腺胃発癌. 第56回日本癌学会総会 (京都), p. 97, 1997
 
26) Sugiyama A et al : Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 58 : 2067-2069, 1998
PubMed
27) Watanabe T et al : Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 115 : 642-648, 1998
PubMed
28) Honda S et al : Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res 58 : 4255-4259, 1998
PubMed
29) Krakowka S et al : Occurrence of gastric ulcers in gnotobiotic piglets colonized by Helicobacter pylori. Infect Immun 63 : 2352-2355, 1995
PubMed
30) Li H et al : Helicobacter pylori (HP) infected rats : a study on infection, inflammation, immunology, apotosis, cell proliferation and gastric ulcer healing. Gastroenterology 122 : A198, 1997
 
31) 南出晃伸ら : ラット急性胃損傷誘起後のHelicobacter pylori感染に関する検討. 第25回日本実験潰瘍学会 (東京), No.54, 1997
 
32) Sturegard E et al : Severe gastritis in Helicobacter pylori-infected guinea pigs. Gut (suppl. 1) 41 : A118 (11/431), 1997
 
33) Shomer NH et al : Guinea pig model of Helicobacter pylori infection. Gut (suppl. 1) 41 : A119 (11/435), 1997
 
34) Queiroz DMM et al : Spiral bacterium associated with gastric, ileal and caecal mucosa of mice. Lab Animals 26 : 288-294, 1992
 
35) Czinn SJ et al : Characterization and therapy for experimental infection by Helicobacter mustelae in ferrets. Helicobacter 1 : 43-51, 1996
PubMed
36) Ward JM et al : Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol 145 : 959-968, 1994
PubMed
37) 高橋信一ら : A novel small model of Helicobacter infection using Helicobacter heilmanii like organism. 第3回日本ヘリコバクターピロリ研究会 (別府), p. 107, 1997
 

第6章 疾患とのかかわり

P.86 掲載の参考文献
1) Dixon MF et al : Classification and grading of gastritis. The updated Sydney System, Intemational Workshop on the Histopathology of gastritis, Houston 1994. Am J Surg, Pathol 20 : 1161-1181, 1996
 
2) Khakoo SI et al : Histological assessment of the sydney classification of endoscopic gastritis. Gut 35 : 1172-1175, 1994
PubMed
3) Belair PA et al : Receiver operator characteristic analysis of endoscopy as a test for gastritis. Dig Dis Sci 42 : 2227-2233, 1997
PubMed
4) Kimura K et al : An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 3 : 87-97, 1969
 
5) Strickland RG et al : A reappraisal of the nature and significance of chronic atrophic gasthtis. Am J Dig Dis 18 : 426-440, 1973
PubMed
6) Graham DY et al : Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. Am J Gastroenterol 83 : 974-980, 1988
PubMed
7) Morris A et al : Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 : 192-199, 1987
PubMed
8) Lee A et al : Local acid production and Helicobacter pylori : a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 7 : 461-465, 1995
PubMed
9) Logan RPH et al : Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36 : 12-16, 1995
 
10) Kuipers EJ et al : Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy : implications for long-term safety. Am J Gastroenterol 90 : 1401-1406, 1995
PubMed
11) Klinkenber-Knol EC et al : Efficacy and safety long-term treatment with omeprazole for refractory reflux esophagitis. Ann Intern Med 121 : 161-167, 1994
 
12) Kinoshita Y et al : Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 41 : 452-458, 1997
PubMed
13) El-Omar EM et al : Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109 : 681-691, 1995
PubMed
14) 後藤豊子ほか : 胃炎の将来像. 消化器科 26 : 52-57, 1998
 
15) Quigley EMM et al : pH of the microclimate lining human gastric and duodenal mucosa in vivo. Gastroenterology 92 : 1876-1884, 1987
 
16) Azuma T et al : Contribution of HLA-DQA gene to host's response to Helicobacter pylori. Lancet 343 : 542-543, 1994
 
17) Sakagami T et al : Atrophic gastric changes in both HelicobacterfeliS and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 39 : 639-648, 1996
 
18) 浅香正博 : Helicobacter pyloriと胃疾患-胃炎, 胃潰瘍, 胃癌を含めて-. Med Pract 12 : 770-778, 1995
 
19) Meining A et al : Defferent expression of Helicobacter pylori gastritis in children : evidence for a specific pediatric disease? Helicobacter 1 : 92-97, 1996
 
20) Valle J et al : Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 31 : 546-550, 1996
PubMed
21) Forbes GM et al : Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol 11 : 670-673, 1996
PubMed
22) Van der Hulst RWM et al : Effect of Helicobacter pylori eradication on gastritis in relation to cagA : a prospective 1-year fbllow-up study. Gastroenterology 113 : 25-30, 1997
 
23) El-Omar ED et al : Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 : 15-24, 1997
 
24) Borody TJ et al : Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. Am J Gastroenterol 88 : 1266-1268, 1993
PubMed
25) Tucci A et al : Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis. N Engl J Med 336 : 957-958, 1997
PubMed
26) Genta RM et al : Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 6 : 281289, 1993
 
27) Hack HM et al : H. pylori, intestinal metaplasia and gastric juice mutagenicity. Gastroenterology 106 : A87 (abstract), 1994
 
28) Uemura N et al : Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarhers Prev 6 : 639-642, 1997
PubMed
P.94 掲載の参考文献
1) Marshall BJ et al : Prospective double blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet ii : 1437-1442, 1988
 
2) Tatsuta M et a1 : Reduction of gastric ulcer recurence after suppression of Helicobacter pylori by cefixime. Gut 31 : 973-976, 1990
 
3) Hirayama F et at : Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J Gastroenterol 31 : 755-757, 1996
PubMed
4) Marshall BJ et al : Attempt to fulfil Koch's postulate for pyloric Campylobacter. Med J Aust 142 : 436-439, 1985
 
5) Morris A et al : Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 : 192-199, 1987
PubMed
6) Kodama R et al : Natural course of H. pylori infection in Japanese monkeys : 7 years follow-up study. Gastroenterology 114 (4) Part 2 : A181, 1998
 
7) Telford JL et al : Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 179 : 1653-1658, 1994
PubMed
8) Lambert JR et al : Prevalence/disease correlates of H. pylori. In : Helicobacter pylori, ed. by Hunt RH et al, Kluwer Academic Publishers, Dordrecht, 1993, pp. 95-112
 
9) Tytgat GNJ et at : Role in peptic ulcer disese (8. Overview). In : Helicobacter pylori infection, ed. by Northfield TC et al, Kluwer Academic Publishers, Dordrecht, 1993, pp. 75-87
 
10) 西川恵子ほか : Helicobacter pylori陰性潰瘍の実体, Helicobacter Res 2 : 314-319, 1998
 
11) 柴田知行ほか : 上部内視鏡施行例の生検部位別Helicobacter pylori検出率. 日本臨牀 51 : 3205-3209, 1993
 
12) 樋口和秀ほか : H. pylori 感染と胃潰瘍. 消化器内視鏡 10 : 1037-1043, 1998
 
13) Oi M et al : A possible dual control mechanism in the origin of peptic ulcer. A study on ulcer location as affected by mucosa and musculature. Gastroenterology 57 : 280-293, 1969
 
14) 井本一郎ほか : 胃炎, 消化性潰瘍, 胃癌の発生病理に関する新たな展開-Helicobacter pylori感染との関連において-. 日本内科学会雑誌 82 : 1447-1451, 1993
 
15) Maaroos HI et al : Grade of Helicobacter pylori colonisation, chronic gastritis and relative risk of contracting high gastric ulcers : a seven-year follow-up. Scand J Gastroenterol 26 (Suppl. 186) : 65-72, 1991.
 
16) Covacci A et al : Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxity and duodenal ulcer. Proc Natl Acad Sci U S A 90 : 5791-5795, 1993
 
17) 小俣政男ほか : H. pylor体邦分離株におけるVacAおよびCagAの検出頻度と病態関連. 日本臨牀 57 : 17-22, 1999
 
18) Miehlke S et al : Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Am J Gastroenterol 91 : 1322-1325, 1996
 
19) Shimoyama T et al : Bacterial factors and immune pathogenesis in Helicobacter pylori infection. Gut 43 (suppl. 1) : S2-5, 1998
 
20) Kawano S et al : Chronic effect of intragastric ammonia on gastric mucosal structUres in rats. Dig DiS Sci 36 : 33-38, 1991
PubMed
21) Sung JJY et al : Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 332 : 139-142, 1995
 
22) Makino M et al : Delayed healing of chronic gastric ulcer after Helicobacter pylori infection in mice. J Pharm Pharmacol 50 : 943-948, 1998
PubMed
23) 安保徹 : 胃潰瘍発症のメカニズム. 治療 80 : 1443-1439, 1998
 
24) 福田能啓ほか : 粘膜防御因子剤を用いたHelicobacter pylori除菌療法. Med Pract 13 : 1917-1927, 1996
Medical*Online
25) Boren T et al : Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 262 : 1892-1895, 1993
PubMed
26) 東健ほか : H. pylori感染における疾患特異性. 消化器内視鏡 10 : 943-947, 1998
 
27) El-Omar E et al : Eradicating, H. pylori lowers gastrin mediated acid secretion by 70% in DU patients and 50% in healthy volunteers. Gastroenterology 104 (suppl. 4) : A75, 1993
 
28) Taguchi Y et al : Helicobacter pylori inhibits the secretory activity of gastric parietal cells in patients with chronic gastritis. Scand J Gastroenterol 32 : 656-663, 1997
PubMed
29) Yasunaga Y et al : Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis. Gut 35 : 1571-1574, 1994
PubMed
30) Labenz J et al : Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 : 1442-1447, 1997
PubMed
31) 浅香正博 : 疫学面からみたヘリコバクター・ピロリ感染の検討. 消化器疾患とヘリコバクター・ピロリ, 竹本忠良監修, 下山孝編, メディカルレビュー社, 東京, 1994, pp. 26-33
 
32) Graham DY : Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer : a model. Gastroenterology 113 : 1983-1991, 1997
 
33) 日本消化器病学会Helicobacter pylori治験検討委員会 : Helicobacter pylori治験ガイドライン. 日本消化器病学会雑誌 96 : 199-207, 1999
Medical*Online
P.104 掲載の参考文献
1) Perez-Perez GI et al : Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Int J Cancer 72 : 453-456, 1997
PubMed
2) Atherton JC et al : CagA+strains of Helicobacter pytori colonise the gastric antra of Rhesus monkeys more density the cag strains, without dfferences in mucosal inflammation [abstract]. Gut 19 (suppl. 2) : A60, 1996
 
3) Blaser MJ : Helicobacters are indigenous to the human stomach : duodenal ulceration is due to changes in gastric microecology in the modem era. Gut 43 : 721-727, 1998
 
4) Correa P et al : Helicobacter pylori in pre-Columbian mummies. Gastroenterology 114 (suppl. 4) : A956, 1998
 
5) Svanes C et al : Incidence of perforated ulcer in Western Norway, 1935-1990 : cohort or period-dependent time trends. Am J Epidemiol 141 : 836-844, 1995
PubMed
6) Sonnenberg A : The occurrence of a cohort phenomenon in peptic ulcer motility from Switzerland. Gastroenterology 86 : 398-401, 1984
 
7) Sonnenberg A et al : Birth cohort analysis of peptic ulcer mortality in Europe. J Chronic Dis 381309-317, 1985
 
8) Aldoori WH et al : Prospective study of diet and the risk of dudenal ulcer in men. Am J Epidemiot 145 : 42-50, 1997
 
9) Aldoori WH et al : A prospective study of alcohol, smoking, caffeine, and the risk of duodenal ulcer in men. Epidemiology 8 : 420-424, 1997
PubMed
10) Cambell S et al : Evidence for ethinic tropism of, Heticobacterpylori. Infect immun 65 : 3708-3712, 1997
 
11) Blaser MJ : Ecology of Helicobacter pylori in the human stomach. J Clin Invest 100 : 759-762, 1997
PubMed
12) Atherton JC : The clinical relevance of strain types of Helicobacter pylori. Gut 40 : 701-703, 1997
PubMed
13) van Doorn IJ et al : Typing of the Helicobacter pylori vacA gene and detection of the cagA gene by PCR and reverse hybridization. J Clin Microbiol 36 : 1271-1276, 1998
 
14) Atherton JC et al : Clinical and pathological importance of heterogeneity in vac., 4, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 112 : 92-99, 1997
 
15) Hamlet A et al : Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Gastroenterology 116 : 259-268, 1999
PubMed
16) Tomb JF et al : The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 : 539-547, 1997
PubMed
17) van der Ende A et al : CagA positive Helicobacter pylori populations in China and the Netherlands are distinct. Infect Immun 66 : 1822-1826, 1998
PubMed
18) Van Doorn L-J et al : Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 116 : 823-830, 1999
PubMed
19) Garenne M et al : Pattem of exposure and measles mortality in Senegal. J Infect DiS 161 : 1088-1094, 1990
 
20) Levin BR : The evolution and maintenance of virulence in microparasites, Emerg Infect Dis 2 : 93-102, 1996
PubMed
21) Jorgensen M et al : Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients : identification from sequential and multiple biopsy specimens. J Infect Dis 174 : 631-635, 1996
PubMed
22) Akopyants NS et al : Adaptive mutation and colonization during Helicobacter pylori infection of gnotobiotic piglets. Infect Immun 63 : 116-121, 1995
PubMed
23) Dubois A et al : Host specificity of Helicobacter pylori strains and host responses in experimentally challenged nonhuman primates. Gastroenterology 116 : 90-96, 1999
PubMed
24) Blaser MJ et al : CagA and the outcome of Helicobacter pylori infection. Am J Clin Pathol 106 : 563-567, 1996
 
25) Pan Z-j et al : Equally high prevalences of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol 35 : 1344-1347, 1997
PubMed
26) Mitchell HM et al : Serological response to specific Helicobacter pylori antigens : antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 91 : 1785-1788, 1996
PubMed
27) Heilmann KL et al : Gastritis due to spiral shaped bacteria other than Helicobacter pylori : clinical, histological, and ultrastructual findings. Gut 32 : 137-140, 1991
 
28) Dubois A et al : Natural gastric infection with Helicobacter pylori in monkeys. A model for human infection with spiral bacteria. Gastroenterology 106 : 1405-1417, 1994
 
29) Solnick JV et al : An uncultured gastric spiral organism is a newly identified Helicobacter pylori in humans. J Infect Dis 168 : 379-385, 1993
PubMed
30) Stolte M et al : Helicobacter heilmanni (formerly Gastrospirillum hominis) gastritis : an infection transmitted by animal? Scand J Gastroenterol 29 : 1061-1054, 1994
 
31) Correa P et al : The relationship between gastric cancer frequency and the ratio of gastriic to duodenal ulcer. Aliment Pharmacol Ther 9 (suppl. 2) : 13-19, 1995
 
32) Sonnenberg A : Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther 9 (suppl. 2) : 3-12, 1995
 
33) Blaser V J et al : Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 55 : 562-565, 1995
 
34) Personnet J : Incidence of, Helicobacter pylori infection. Aliment Pharmacol Ther 9 (suppl. 2) : 45-51, 1995
 
35) Goodman KI et al : Helicobacter pylori in the Colombian Andesw : a population-based study of transmission pathways. Am J Epidemiol 144 : 290-299, 1996
 
36) Mendall MA et al : Childhood living conditions and Helicobacter pylori seropositivity in adult life. Lancet 339 : 896-897, 1992
PubMed
37) Goodman Kl et al : Transmission of H. pylori infection among siblings in a Colombian village. In : Abstracts, Helicobacter pylori : basic mechanisms to clinical care 1998, ed. by AxCan Pharma, Montreal, Canada, 1998
 
38) Lee A et al : Effect of gastric acid on Helicobacter pylori ecology. In : Helicobacter pylori : basic mechanisms to clinical cure 1996, ed. by Hunt RH et al, Kluwer, Dordrecht, 1996, pp. 50-63
 
39) Gillen D et al : The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 114 : 50-57, 1998
PubMed
40) Isenberg JI et al : Acid-peptic disorders. In : Textbook of gastroenterology, ed. by Yamada T, JB Lippincott, Philadelphia, 1995, pp. 1347-1430
 
41) El-Omar EM et al : Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109 : 681-691, 1995
PubMed
42) Graham DY : Helicobacter pylori and perturbations in acid secretion : the end of the bigining. Gastroenterology 110 : 1647-1650, 1996
 
43) Calam J et al : How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 113 : S43-49, 1997
PubMed
44) Olbe L et al : A mechanism by which Helicobacter pylori infection of the antrum contributing to the development of duodenal ulcer. Gastroenterology 110 : 1386-1394, 1996
 
45) Sumii M et al : Expression of antral gastrin and somatosatin mRNA in Helicobacter pylori-infected subjects. Am J Gastroenterol 89 : 1515-1519, 1994
 
46) Odum L et al : Gastrin and somatostatin in Helicobacter pylori-infected antral mucosa. Gut 35 : 615-618, 1994
PubMed
47) Queriroz DM et al : Effect of Helicobacter pylori eradication on G-cell nd D-cell density in children. Lancet 343 : 1191-1193, 1994
 
48) Queiroz DMM et al : Effect of Helicobacter pylori eradication on antral gastrin and somatostatin immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 28 : 858-864, 1993
 
49) El-Omar E et al : Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two-thirds in patients with duodenal ulcer. Gut 34 : 1060-1065, 1993
PubMed
50) McColl KEL et al : Plasma gastrin, daytime Intragastric pH, and noctumal acid output before and 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol 26 : 339-346, 1991
 
51) Harris AW et al : Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmcol Ther 11 : 331-334, 1997
 
52) Sipponen P et al : Cumulative 10 year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. Scand J Gastroenterol 25 : 866-973, 1990
PubMed
53) Valle J et al : Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32 year follow-up study. Scand J Gastroenterol 31 : 546-550, 1996
PubMed
54) Dixon MF : Pathophysiology of Helicobacter infection. Scand J Gastroenterol 29 (suppl. 201) : 7-10, 1994
 
55) Crabtree JE et al : Mucosal tumor necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori- associated gastritis. Gut 32 : 1473-1477, 1991
PubMed
56) Crabtree JE et al : CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 47 : 945-950, 1994
 
57) Noach LA et al : Mucosal tumour necrosis factor-a, interleuldn-1b, and interleukin-8 production in patients with, Helicobacter pylori infection. Scand J Gastroenterol 29 : 425-429, 1994
 
58) Khulusi S et al : Pathogenesis of gastric metaplasia of the human duodenum : role of Helicobacter pylori gastric acid, and ulceration. Gastroenterology 110 : 452-458, 1996
PubMed
59) Wyatt JI et al : Gastric epithelium in the duodenum : Its association with Helicobacter pylori and Inflammation. J Clin Pathol 43 : 981-986, 1990
PubMed
60) Kohda K et al : Role of apoptosis induced by Helicobacter pylori infection in the development of duodenal ulcer. Gut 44 : 456-462, 1999
PubMed
61) Walker MM et al : Gastric metaplasia : Its role in duodenal ulceration. Aliment Pharmacol Ther 10 (Suppl. 1) : 119-128, 1996
 
62) Khulusi S et al : Pathogenesis of gastric metaplasia of the human duodenum : role of Helicobacter pylori gastric acid, and ulceration. Gastroenterology 110 : 452-458, 1996
PubMed
63) Savarino V et al : 24-hour gastric pH and extent of duodenal gastric metaplasia in Helicobacter pylori -positive patients. Gastroenterology 113 : 741-745, 1997
PubMed
64) Carrick J et al : Campylobacter pylori, duodenal ulcer, and gastric metaplasia : Poosible role of functional heterotopic tissue in ulcerogenesis. Gut 30 : 790-797, 1989
 
65) Veldhuyzen SJO et al : The gastric transitional zones : negelected links between gastroduodenal pathology and Helicobacter ecology, Gastroenterology 116 : 1217-1229, 1999
 
66) Feldman M : Gastric secretion in health and disease. In : Gastrointestinal disease, ed. by Sleisenger MH et al, WB Saunders, Philadelphia, 1989, pp. 713-734
 
67) Calm J et al : How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiolosy. Gastroenterology 113 : S43-49, 1997
 
68) Isenberg JI et al : Acid-peptic disorders. In : Textbook of gastroenterology, ed. by Yamada T, JB Lippincott, Philadelphia, 1995, pp. 1347-1430
 
P.114 掲載の参考文献
1) Asaka M et al : Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102 : 760-766, 1992
 
2) 今野武津子 : 小児の胃炎・十二指腸潰瘍とのかかわり. Helicobacter pyloriと胃粘膜病変, 浅香正博編, 先端医学社, 東京, 1995, pp. 81-88
 
3) Genta RM et al : Gastric lymphoid follicles in Helicobacter pylori infection. Hum Pathol 24 : 577-583, 1993
PubMed
4) Sugiyama T : Local immune response of gastric mucosa to Helicobacter pylori infection with and without intestinal metaplasia. Eur J Gastroenterol Hepatol 5 : 119-122, 1993
 
5) Kato S et al : Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics 100 : E31-35, 1997
 
6) Tursi A et al : Long-term follow-up of disappearance of gastric mucosa-associated lymphoid tissue after anti-Helicobacter pylori therapy. Am J Gastroenterol 92 : 1849-1852, 1997
PubMed
7) Marshall GJ et al : Attempt to fulfil Koch's postulates for pylori c campylobacter. Med J Aust 142 : 436-439, 1985
 
8) Morris A et al : Ingestion of Campylobacter pylori dis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 : 192-199, 1987
 
9) Macarthur C et al : Helicobacter pylori gastroduodenal disease, and recurrent abdominal pain. JAMA 273 : 729-734, 1995
PubMed
10) Kato S et al : Ethcacy of twice-daily cimetidine in pediatric peptic ulcer. J, Pediatr Gastroenterol Nutr 18 : 288-293, 1994
PubMed
11) 加藤晴一 : 胃十二指腸潰瘍. 小児科診療 10 : 1739-1743, 1995
 
12) Dixon MF : Helicobacter pylori and acid peptic disease. In : Helicobacter pylori, its role in gastrointestinal disease, ed. by Axon ATR, Science press, London, 1994, pp. 18-34
 
13) Marshall BJ et al : Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet ii : 1437-1442, 1988
 
14) Graham DY et al : Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28 : 939-942, 1993
PubMed
15) Drumm B et at : Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 322 : 359-363, 1990
PubMed
16) Hassall E et al : Unique features of Helicobacter pylori desease in children. Dig Dis Sci 36 : 417-423, 1991
 
17) Czinn S : Helicobacter pylori gastroduodenal disease in infants and children. 日本小児栄養消化器病学会雑誌 9 : 1-7, 1995
 
18) Wyatt JI : Helicobacter pylori, duodenitis and duodenal ulceration. In : Helicobacter pylori and gastroduodenal disease, ed. by Rathbone BJ et al, Backwell Scientific Publications, London, 1992, pp. 140-149
 
19) Yeung CK et al : Helicobacter pylori and associated duodenal ulcer. Arch DiS Child 65 : 1212-1216, 1990
PubMed
20) Shabib S et al : Association and gastric metaplasia and duodenitis with Helicobacter pytori infection in children. Am J Clin Pathol 102 : 188-191, 1994
PubMed
21) Queiroz DM et al : Effect of Helicobacter pylori eradication on antral gastrin- and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 28 : 858-864, 1993
PubMed
22) Crabtree JE et al : Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol 48 : 41-45, 1995
PubMed
23) Cover TL et al : Characterization of human serologic response to proteins in」Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun 58 : 603-610, 1990
 
24) Graham DY et al : Serum CagA antibodies in asymptomatic subjects and patients with peptic ulcer : lack of correlation of IgG antibody in patients with peptic ulcer or asymptomatic Helicobacter pylori gastritis. J Clin Pathol 49 : 829-832, 1996
PubMed
25) Kato S et al : Seropositivity of CagA antibody in Japanese children with nodular gastritis and peptic ulcer dicease. Gastroenterology 116 : A206, 1999
 
26) Kato S et al : Effectiveness and pharmacokinetics of omeprazole in children with refractory duodenal ulcer. J Pediatr Gastroenterol Nutr 15 : 184-188, 1992
PubMed
27) Sherman PM : Peptic ulcer disease in children. Diagnosis, treatment, and the implication of Heticobacter pylori. Gastroenterol Clin North Am 23 : 707-725, 1994
PubMed
28) Mahony MJ et al : Management and response to treatment of Helicobacter pylori gastritis. Arch Disohild 67 : 940-943, 1992
PubMed
29) Kato S et al : Effect of omeprazole in the treatment of refractory acid-related diseases in childhood : endoscopic healing and 24-hour intragastric acidity. J Pediatr 128 : 415-421, 1996
PubMed
30) NIH Consensus Conference : Helicobacter pylori in peptic ulcer disease. JAMA 272 : 65-69, 1994
 
31) Malfertheiner P et al : Current European concepts in the management of Helicobacter pylori infection : the Maastricht consensus report. Eur J Gastroenterol Hepatol 9 : 1-2, 1997
PubMed
32) Dohil R et al : Effective 2-week therapy for Helicobacter pylori disease in children. Am J Gastroenterol 92 : 244-247, 1997
 
33) Kato S et al : Saiety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children with peptic ulcer disease. Helicobacter 3 : 278-282, 1998
 
34) Kato S et al : Helicobacter pylori reinfection rates in children after eradication therapy. J Pediatr Gastroenterot Nutr 27 : 543-546, 1998
 
35) 加藤晴一ほか : 小児のHelicobacter Pylori除菌療法に関するガイドライン (案) の提唱. 日本小児栄養消化器病学会雑誌 11 : 173-176, 1997
Medical*Online
36) Rawland M et al : Reinfection With Helicobacterpylori in children. Gastroenterology 112 : A273, 1997
 
P.125 掲載の参考文献
1) Kimura K : Chronological transition of the fundic-pylori c border determined by stepwise biopsy of the lessor and greater curvatures of the stomach. Gastroenterology 63 : 584-592, 1972
 
2) Kimura K et al : Chronological extension of atrophic gastritis and intestinal metaplasia in Japanese. Eur J Gastroenterol Hepatol 5 (suppl. 1) : S85-91, 1993
 
3) Kuipers EJ et al : Long-term sequelae of Helicobacter pylori gastritis. Lanset 345 : 1525-1528, 1995
 
4) Sakaki N : The influence of Helicobacter pylori infection on the progression of gastric mucosal atrophy and occurrence of gastric cancer. Eur J Gastroenterol Hepatol 7 (suppl. 1) : S59, 1995
 
5) Niemela S et al :, Helicobacter pylori-associated gastritis. Evolution of histologic changes over 10 years. Scand J Gastroenterol 30 : 542-549, 1995
PubMed
6) Niemela S et al : Chronic gastritis in patients with gastric ulcer ; a 10-year follow-up. Scand J Gastroenterol 30 : 428-433, 1995
PubMed
7) Asaka M et al : Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than the aging in asymptomatic Japanese adults. Helicobacter 1 : 52-56, 1996
 
8) Fujioka T et al : Experimental model for chronic gastritis with Helicobacter pylori : long-tem follow-up study in H. pylori infected Japanese macaques. Eur J Gastroenterol Hepatol 5 (suppl. 1) : S73-77, 1993
 
9) Hirayama F et al : Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J Gastroenterol 31 : 755-757, 1996
PubMed
10) Blaser MJ : Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 102 : 720-727, 1992
 
11) Glupczynski Y et al : Use of urea breath test versus invasive methods to determine the prevalence of Helicobacter pylori in Zaire. Eur J Clin Microbiol Infect Dis 11 : 322-327, 1992
PubMed
12) Gill HH et al : Helicobacter pylori and gastroduodenal disorders in India-Lessons from epidemiology. J Clin Gastroenterol 16 : 6-9, 1993
PubMed
13) Holcombe C et al : H. pylori, the most common bacterial infection in Africa : a random serological study. Am J Gastroenterol 87 : 28-30, 1992
 
14) Wyle FA et al : Do strains of Helicobacter pylori differ from one another. Eur J Gastroenterol Hepatol 5 (suppl. 1) : S9-S15, 1993
 
15) Marchetti M et al : Helicobacter pylori infection in a mouse model that mimics human disease. Science 267 : 1655-1658, 1995
 
16) Beales ILP et al : Long-term sequelae of Helicobacter pylori gastritis. Lancet 346 : 381-382, 1995
 
17) Asaka M et al : Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102 : 760-766, 1992
 
18) Sobala GM et al : Simultaneous detemlination of ascorbic acid, nitrate, total nitroso compounds and bile acids in gastric juice, and gastric mucosal histology : implications for gastric carcinogenesis. Carcinogenesis 12 : 193-198, 1991
 
19) Davis GR et al : Adirect relationship between infective load of Helicobacter pylori and oxygen free radical production in antral mucosal biopsies. Gut 34 (suppl. 1) : 73, 1993
 
20) Clemens MR : Free radicals in chemical carcinogenesis. Min Wochenschr 69 : 1123-1134, 1991
 
21) Tsujii M et al : Ammonia : A possible promotor in Helicobacter pylori-related gastric carcinogenesis. Cancer Lett 65 : 15-18, 1992
PubMed
22) Krytopoulos SA : Ascorbic acid and formation of N-nitroso compounds : possible role of ascorbic acid in cancer prevendon. Am J Clin Nutr Cancer 45 (suppl.) : 1344-1350, 1987
 
23) Sobala GM et al : Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut 34 : 1038-1041, 1993
PubMed
24) Correa P : Human gastric carcinogenesis : a multifactorial process-first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52 : 6735-6740, 1992
PubMed
25) International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. LARC Monogr Eval Carcinog Risks, Hum 61 : 177-240, 1994
 
26) Parsonnet J et al. Helicobacter pylori infection and risk of gastric carcinoma. N Engl J Med 325 : 1127-1131, 1991
PubMed
27) Nomura A et al : Helicobacter pylori infection and gastric cancer among Japanese Americans in Hawaii. N Engl J Med 325 : 1132-1136, 1991
PubMed
28) The Eurogast Study Group : An international association between Helicobacter pylori infection and gastric cancer. Lancet 341 : 1359-1362, 1993
 
29) Rudi J et al : Lack of Association of, Helicobacter pylori seroprevalence and gasuic cancer in a population with low gastric cancer incidence. Scand J Gastroenterol 30 : 958-963, 1995
 
30) Asaka M et al : Possible role of Helicobacter pytori infection in early gastric cancer development. Cancer 73 : 2691-2694, 1994
PubMed
31) Kikuchi S et al : Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Cancer 75 : 2789-2793, 1995
PubMed
32) Asaka M et al : What role does Helicobacter」pylori play in gastric cancer? Gastroenterology 113 : S56-S60, 1997
 
33) 胃の悪性新生物. 日本の疾病別総患者数データブック, 厚生省大臣官房統計情報部保健社会統計課保健統計室監修, 厚生統計協会, 東京, 1995, pp. 33
 
34) Cumulative incidence (0-74) rates and standard erros (percent) : Stomach (ICD-9 151). In : Cancer incidence in five continents vol 3, No143, eds. by Parkin DM, IARC Scientific Publications, Lyon, 1997, pp. 972-973
 
35) Watanabe T et al : Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 115 : 642-648, 1998
PubMed
36) Wang TC & Fox JG : Helicobacter pylori and gastric cancer : Koch's postulates fulfilled? (Editovials) Gastroenterology 115 : 780-783, 1998
 
P.135 掲載の参考文献
1) Isaacson PG et al : Malignant lymphoma of mucosa associated lymphoid tissue. Cancer 52 : 1410-1416, 1983
 
2) 神津隆弘ほか : 胃MALTリンパ腫とH. pylori感染. 消化器科 24 : 281-287, 1997
 
3) Cammarota G et al : The growth of primary low-grade B-cell gastric lymphoma is sustained by Helicobacter pylori. Scand J Gastroenterol 32 : 285-287, 1997
PubMed
4) Enno A et al : MALToma-Like Lesions in the Murine Gastric Mucosa after Long-Term Infection with Helicobacter felis-A Mouse Model of Helicobacter pylori induced Gastric Lymphoma. Am J Pathol 147 : 217-222, 1995
PubMed
5) The European Helicobacter pylori study group (EHPSG) : Current European concepts in the management of Helicobacter pylori infection. The Maastricht consesus report. Gut 41 : 8-13, 1997
 
6) Wotherspoon AC et al : Trisomy 3 in low-grade B-ce111ymphomas of mucosa-associated lymphoid tissue. Blood 85 : 2000-2003, 1995
PubMed
7) 渡辺英伸ほか : 胃MALTリンパ腫の病理形態診断. 胃と腸 31 : 15-24, 1996
 
8) Vanagunas A : Eradication of Helicobacter pylori and regression of B-cell lymphoma. Biomed Pharmacother 51 : 156-160, 1997
PubMed
9) Franzin G et al : Gastric MALT low-grade lymphoma : follow-up study after eradication of Helicobacter pylori. Gastroenterology 11 : A109, 1996
 
10) Savio A et al : Diagnosis and Posttreatment Follow-up of Helicobacter pylori-Positive Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue : Histology, Polymerase Chain Reaction, or Both? Blood 87 : 1255-1260, 1996
PubMed
11) Montalban C et al : Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma : Follow-up together with sequential molecular stUdies. Ann Oncol 8 (Suppl. 2) : S37-39, 1997
 
12) Hsi ED et al : Detection of immunoglobulin heavy chain gene rearrangement by polymerase chain reaction in chronic active gastritis associated with Helicobacter pylori. Hum Pathol 27 : 290-296, 1996
PubMed
13) 比島恒和 : 悪性リンパ腫との関連. 臨床と微生物 24 : 329-333, 1997
Medical*Online
14) Seymour JF et al : Regression of Gastric Lymphoma with Therapy for Helicobacter pylori Infection. Ann Intern Med 127 : 247, 1997
PubMed
P.141 掲載の参考文献
1) 大原秀一ほか : 老年逆流性食道炎における胃粘膜萎縮とHelicobacter Pylori感染. 日本消化器病学会雑誌 93 : 235-239, 1996
 
2) Mihara M et al : Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis [abstract]. Gut 39 (suppl.) : A94, 1996
 
3) Labenz J et al : Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 : 1442-1447, 1997
PubMed
4) 平井雅道ほか : Helicobacter pylori除菌治療後に新たに発生した逆流性食道炎の3例. Gastroenterol Endosc 39 : 1630-1633, 1997
 
5) Jaup BH et al : 1-week bid therapy for H. pylori : a randomized comparison of 3 different strategies on clinical outcome and side-effects. Gut 41 (Suppl.) : A209, 1997
 
6) Graham DY et al : Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race and socioeconomic status. Gastroenterology 100 : 1495-1501, 1991
 
7) Hesketh PJ et al : The increasing frequency of adenocarcinoma of the esophagus. Cancer 64 : 526-530, 1989
PubMed
8) Prach AT et al : Increasing incidence of Barrett's oesophagus : education, enthusiasm or epidemiology? Lancet 350 : 933, 1997
PubMed
9) Mittal RK et al : Transient lower esophageal sphincter relaxation. Gastroenterology 109 : 601-610, 1995
PubMed
10) Noach LA et al : Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 29 : 425-429, 1994
PubMed
11) Wilson M et al : Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. Gastroenterology 111 : 1524-1533, 1996
 
12) Boulant J et al : Cholecystokinin and nitric oxide in transient lower esophageal sphincter relaxa60n to gasuic distention in dog. Gastroenterology 107 : 1059-1066, 1994
PubMed
13) Preikseitis HG et al : Nitric oxide mediates inhibitory nerve effects in human esophagus and lower esophageal sphincter. Dig Dis Sci 39 : 770-775, 1994
 
14) Morgan GP : Deleterious effects of prostaglandin E2 in reflux esophagitis. Med Hypotheses 46 : 42-44, 1996
 
15) McCallum RW et al : Gastric emptying in patients With gastroesophageal reflux. Gastroenterology 80 : 285-291, 1981
PubMed
16) Qvist N et al : Helicobacter pylori-associated gastritis and dyspepsia. The influence on migrating motor complexes, Scand J Gastroenterol 29 : 133-137, 1994
PubMed
17) Kao CH et al : The relationship between Helicobacter pylori-associated gastritis or ulcer disease and gastric emptying. Eur J Nucl Med 21 : 209-211, 1994
PubMed
18) Labenz J et al : Helicobacter pylori in gastro-oesophageal reflux disease : causal agent, independent or protective factor? Gut 41 : 277-280, 1997
PubMed
19) Beil W et at : Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K+ -ATPase. Gut 25 : 1176-1180, 1994
 
20) Cave DR et al : Effect of a Campylobacter pylori protein on acid secretion by parietal cells. Lancet 22 : 187-189, 1989
 
21) EL-Omar EM et al : Helicobacter pylori infection and gastric acid hyposecretion. Gastroenterology 113 : 15-24, 1997
PubMed
22) Esplugues JV et al : Nitric oxide mediates the inhibition by interleukin-1 beta of pentagastrin-stimulated rat gastric acid secretion. Br J Pharmacol 108 : 9-10, 1993
PubMed
23) Robert A et al : Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci 48 : 123-134, 1991
PubMed
24) Pfeiffer A et al : Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease. Gut 36 : 813-818, 1995
PubMed
25) Labenz J et al : Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 : 1442-1447, 1997
PubMed
26) Schnell JW et al : Helicobacter pylori CagA strains predominate in gastroesophageal refiux disease, Barrett's esophagus, and esophageal dysplasia/adenocarcinoma. Gastroenterology 112 (Suppl.) : A283, 1997
 
27) Reynolds JC : Individualized acute treatment for gastroesophageal reflux disease. Scand J Gastroenterol 30 (suppl. 213) : 17-24, 1995
 
28) Kuipers EJ et al : Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Eng J Med 334 : 1018-1022, 1996
 
29) Carlsson R et al : Does H. pylori infection influence the response to treatment with acid inhibition in patients with gastroesophageal reflux disease (GERD)? Scand J Gastroenterol 32 (Suppl.) : F70, 1997
 
30) Kinoshita Y et al : Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 41 : 452-458, 1997
PubMed
P.149 掲載の参考文献
1) Mendell MA et al : Relation of Heticobacter pylori infection and coronary heart disease. Br Heart J 71 : 437-439, 1994
 
2) Patel P et al : Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 311 : 711-714, 1995
 
3) Martin-de-Argila C et at : High seroprevalence of Helicobacter pylori in coronary heart disease. Lancet 346 : 310, 1995
 
4) Lip GYH et al : G. Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H. pylori infection and hypertension. Br Med J 312 : 250-251, 1996
 
5) Ponzetto A et al : Association of Helicobacter pylori infection with coronary heart disease. Study confirms previous findings. Br Med J 312 : 251, 1996
 
6) Murray LJ et al : Helicobacter pylori infection : relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J 74 : 497-501, 1995
PubMed
7) Niemela S et al : Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 75 : 573-575, 1996
PubMed
8) Whincup PH et al : Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart 75 : 568-572, 1996
PubMed
9) Miragliotta G et al : Helicobacter pylori infection and coronary heart disease. Lancet 344 : 751, 1994
PubMed
10) Sandifer Q et al : Association of Helicobacter pylori infection with coronary heart disease. Association may not be causal. Br Med J 312 : 251, 1996
PubMed
11) Patel P et al : Helicobacter pylori infection in childhood : risk factors and effect on growth. Br Med J 309 : 1119-1123, 1994
 
12) Marks R et al : Gastrointestinal observations in Rosacea. Lancet i : 739-742, 1967
PubMed
13) Rebora A et at : Helicobacter pylori in patients with rosacea. Am J Gastroenterol 89 : 1603-1604, 1994
PubMed
14) Parish LC Witkowski JA : Acne rosacea and Helicobacter pylori betrothed. Int J Dermatol 34 : 236, 1995
PubMed
15) Lopez-Brea M et al : Urticaria associated with Campyrobacter enteritis. Lancet i : 1354, 1984
 
16) Rebora A et al : May Helicobacter pylori be important for dermatologists? Demaatotogy 191 : 6-8, 1995
PubMed
17) Reinauer S et al : Schonlein-Henoch purpura associated with gastric Helicobacter pylori infection. J Am Acad Dermatol 33 : 876-879, 1995
PubMed
18) Gubbins GP et al : Helicobacter pylori is a risk factor for hepatic encephalopathy in acute alcoholic hepatitis : The ammonia hypothesis revised. Am J Gastroenterol 88 : 1906-1910, 1993
 
19) Ito S et al : Hyperammonaemia and Helicobacter pylori. Lancet 346 : 124-125, 1995
PubMed
20) Plevris JN et al : Hyperammonaemia in cirrhosis and Helicobacter pylori infection. Lancet 346 : 1104, 1995
PubMed
21) Quero JC et al : Hyperammonaemia and Helicobacter pylori. Lancet 346 : 713-714, 1995
PubMed
22) Miyaji H et al : Effects of Helicobacter pylori eradication therapy on hyperammonaemia in patients with liver cirrhosis. Gut 40 : 726-730, 1997
 
23) Ward JM et al : Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst 86 : 1222-1227, 1994
PubMed
24) Ward JM et al : Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol 145 : 959-968, 1994
PubMed
25) Ward JM et al : Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. Lab/ Anim Sci 46 : 15-20, 1996
PubMed
26) Ward JM et al : Autoimmunity in chronic active Helicobacter hepatitis of mice. Serum antibodies and expression of heat shock protein 70 in liver. Am J Pathol 148 : 509-517, 1996
PubMed
27) Fox JG et al : Chronic proliferative hepatitis in A/JCr Mice associated with persistent Helicobacter hepaticus infection : a model of Helicobacter-induced carcinogenesis. Infect Immun 64 : 1548-1558, 1996
 
28) Fox JG et al : Persistent hepatitis and enterocolitis in germfree mice infected with, Helicobacter hepaticus. Infect Immun 64 : 3673-3681, 1996
PubMed
29) Nguyen AM et al : Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction. J Clin Microbiol 31 : 783-787, 1993
PubMed
30) Shimada T et al : Identhication of Helicobacter pylori in gastric specimens, gastric juice, saliva, and faeces of Japanese patients. Lancet 343 : 1636-1637, 1994
PubMed
31) lshihara K et al : 0ral bacteria inhibit Helicobacter pylori growth. FEMS Microbiol Lett 152 : 355-361, 1997
 
32) Raderer M et al : Association between Helicobacter pylori infection and pancreatic cancer. Oncology 55 : 16-19, 1998
PubMed
33) Pasceri V et al : Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 97 : 1675-1679, 1998
PubMed
34) Danesh J et al : Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus : population based study of coronary heart disease. Heart 81 : 245-247, 1999
 
35) Torgano G et al : Treatment of, Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 99 : 1555-1559, 1999
PubMed
36) Markus HS et al : Helicobacter pylori infection : a risk factor for ischaemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry64 : 104-107, 1998
 
37) Gasbarrini A et al : Association of, Helicobacter pylori infection with primary Raynaud phenomenon. Lancet 348 : 966-967, 1996
PubMed
38) Gasbarrini A et al : Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon. Dig Dis Sci 43 : 1641-1645, 1998
 
39) Di Campli C et al : Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 43 : 1226-1229, 1998
PubMed
40) Murakami K et al : Atopic dermatitis successfully treated by eradication of Helicobacter pylori. J Gastroenterol 31 (Suppl. 9) : 77-82, 1996
 
41) Figura N et al : Most Helicobacter pylori infected patients have spechic antibodies, and some also have H. pylori antigens and genomic material in bile. Dig Dis Sci 43 : 854-862, 1998
 
42) Fox JG et al : Hepatic Heticobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 114 : 755-763, 1998
PubMed
43) Marignani M et al : Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. Scand J Gastroenterol 32 : 617-622, 1997
PubMed
44) Peach HG et al : Helicobacter pylori infection : an added stressor on iron status of women in the community. Med J Aust 169 : 188-190, 1998
PubMed
45) Milman N et al : Serum ferritin, hemoglobin, and Helicobacter pylori infection : a seroepidemiologic survey comprising 2794 Danish adults. Gastroenterology 115 : 268-274, 1998
PubMed
46) Gasbarrini A et al : Primary headache and Helicobacter pylori. Int J Angiol 7 : 310-312, 1998
PubMed
47) Gasbarrini A et al : Beneficial effects of Helicobacter pylori eradication on migrane. Hepatogastroenterology 45 : 765-770, 1998
 
48) De Luis DA et al : Helicobacter pylori infection is markedly increased in patients with autoimmune atrophic thyroiditis. J Clin Gastroenterol 26 : 259-263, 1998
PubMed
49) Gasbarrini A et al : Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352 : 878, 1998
PubMed
50) Frigo P et al : Hyperemesis gravidarum associated with Helicobacter pylori serepositivity. Obstet Gynecol 91 : 615-617, 1998
 
51) Realdi G et al : Extradigestive manifestations of Helicobacter pylori infection. Fact and fiction. Dig Dis Sci 44 : 229-236, 1999
PubMed

第7章 診断

P.166 掲載の参考文献
1) 福田能啓ほか : Helicobacter pyloriの存在診断と除菌判定. Helicobacter pylori治験ガイドライン, 日本消化器病学会編, 日本消化器病学会, 東京, 1995, pp. 10-11
 
2) 福田能啓ほか : Helicobacter Pylori診断における迅速ウレアーゼキット (CLOテスト) と血清抗体測定キット (Helico-G ELISAキット) の有用性の検討. 基礎と臨床 27 : 3336-3347, 1993
 
3) 奥井雅憲ほか : 全血を用いた血中抗Helicobacter pylori抗体検出キットZYC-101の有用性. 基礎と臨床 30 : 2093-2101, 1996
Medical*Online
4) Kosunen TU et al : Diagnostic value of decreasing IgG, IgA and IgM antibody titers after eradication of Helicobacter pylori. Lancet 339 : 893-895, 1992
 
5) Glupczynski Y et al : Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection. Eur J Clin Microbiol Infect Dis 11 : 583-588, 1992
 
6) Wang WM et al : Long term follow up and serological study after triple therapy of Helicobacter pylori associated duodenal ulcer. Am J Gastroenterol 89 : 1793-1796, 1994
PubMed
7) Cover TL et al : Purilication and characterization of the vacuolating toxin from Helicobacter pylori. J Biolohem 267 : 10570-10575, 1992
PubMed
8) Phadnis SH et al : Pathological signficance and molecular characterization of the vacuolationg toxin gene of Helicobacter pylori. Infect Immun 62 : 1557-1565, 1994
 
9) Xiang Z et al : Detection in an enzyme Immunoassay of an immune response to a recombinant fragment of the 128 kilo-Dalton protein (Cag A) of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 12 : 739, 1993
 
10) Blaser MJ et al : Infection with Helicobacter pylori strains possessing Cag A is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 55 : 2111, 1995
 
P.172 掲載の参考文献
1) McNulty CAM et al : Rapid diagnosis of Campylobacter-associated gastritis. Lancet i : 1443-1444, 1985
 
2) Marshall BJ et al : Rapid urease test in the management of Campylobacter pylori dis associated gastritis. Am J Gastroenterol 82 : 200-210, 1987
 
3) K Nishikawa et al : Evaluation of rapid urease test for, Helicobacter pylori in biopsy specimens, compared with culture and 13C-urea breath test. Gastroenterology 110 : A212, 1996
 
4) El-Zimaity HMT et al : Confirmation of successful therapy of Helicobacter pylori infection : Number and site of biopsies or a rapid urease test. Am J Gastroenterol 90 : 1962-1964, 1995
PubMed
5) Chu K et al : A prospective comparison of locally made rapid urease test and histology for the diagnosis of Helicobacter pylori infection. Gastrointest Endosc 46 : 503-506, 1997
 
6) Rogge JD et al : Evaluation of a new reagent strip for detection of Helicobacter pylori in gastric biopsy specimens. Am J Gastroenterol 90 : 1965-1968, 1995
PubMed
7) Laine L et al : Prospective comparison of commercially available rapid urease rests for the diagnosis of Helicobacter pylori. Gastrointest Endosc 44 : 523-526, 1996
 
8) Yousfi MM et al : Evaluation of a new reagent strip rapid urease test for detection of Helicobacter pylori infection. Gastrointest, Endosc 44 : 519-522, 1996
PubMed
9) Young EL et al : Prospective evaluation of a new urea-membrane test for the detection of Helicobacter pylori in gastric antral tissue. Gastrointest Endosc 44 : 527-531, 1996
PubMed
10) Puetz T et al : The pylori tek test and the CLOtest : accuracy and incremental cost analysis. Am J Gastroenterol 92 : 254-257, 1997
 
11) 星野尚久ほか : Helicobacter pyloriに対する新しいrapid urease test "Pyloritek test kit" の使用経験とその評価. 医学と薬学 34 : 1043-1049, 1995
Medical*Online
12) 都築祐子ほか : Helicobacter pylori検出用PyloriTek Kitの臨床的有用性の検討. 基礎と臨床 30 : 2635-2643, 1996
Medical*Online
13) 西川恵子ほか : 新しいウレアーゼテストの有用性の検討. 消化器内視鏡 9 : 395-399, 1997
 
14) 西川恵子ほか : H. Pytori感染診断における新しい迅速ウレアーゼテスト (MRウレアS) の有用性の検討. 基礎と臨床 74 : 231-233, 1997
 
15) 西川恵子ほか : H. pylori憾染診断におけるラピッドウレアーゼテストの有用性についての検討. 消化器病UP TO DATE, 永井書店, 大阪, 1997, pp. 196-199
 
16) Rollan A et al : Accuracy of invasive and non invasive test to diagnose Helicobacter pylori infection after antibiotic treatment. Am J Gastroenterol 92 : 1268-1274, 1997
PubMed
17) 土山知也ほか : Helicobacter pylori診断におけるmodified rapid urease testの検討. 日本消化器病学会雑誌 94 : 718, 1997
 
18) Murata H et al : Evaluation of the PyloriTek Test for Detection of Helicobacter pylori Infection in Cases With and Without Eradication Therapy. Am J Gastroenterol 93 : 2102-2105, 1998
PubMed
19) 山崎幸直ほか : 新しい高感度迅速ウレアーゼテストによるHelicobacter Pylori : 除菌判定への応用-ピロリテック(R) テストキットを用いて-. 消化器内視鏡 10 : 517-522, 1998
 
20) Kohli Y et al : Endoscopic diagnosis of Helicobacter pylori distribution in human gastric mucosa in vivo. Dig Endosc 3 : 457-460, 1991
 
21) 木村修二ほか : 赤キャベツ色素を利用したHelicobacter Pylori胃内分布可視化の試み. 日本消化器病学会雑誌 87 : 1577, 1990
 
22) 西川恵子 : ウレアーゼテスト. ヘリコバクター・ピロリ-最新知見からの報告-, 原澤茂ほか編, 医薬ジャーナル社, 大阪, 1996, pp94-102
 
P.178 掲載の参考文献
1) Sahay P et al : Reservoirs of Helicobacter pylori and modes of transmission. Helicobacter 1 : 175-182, 1996
PubMed
2) Natalia S et al : Corrected identity of isolates of Helicobacter pylori reference strain NCTC 11637. Helicobacter 2 : 48-52, 1997
 
3) Jiang Q et al : Variability of gene order in different Helicobacter pylori strains contributes to diversity. Mol Microbiol 20 : 833-842, 1996
PubMed
4) Kawamata O et al : Nested-polymerase chain reacdon for the detection of Helicobacter pylori infection with novel primers designed by sequence analysis of urease A gene in clinically isolated bacterial strains. Biochem Biophys Res Commun 219 : 266-272, 1996
PubMed
5) Li C et al : Differentiation of Helicobacter pylori strains directly from gastric biopsy specimens by PCR-based restriction fragment length polymorphism analysis without culture. J Clin, Microbiol 35 : 3021-3025, 1997
PubMed
6) 村岡宏江ほか : 胃粘膜試料より分離したurease非産生Helicobacter pylori について. 感染症学雑誌 71 : 1216-1220, 1997
 
7) 藤井暢弘ほか : サイトトキシンと胃粘膜傷害. G. I. Res 4 : 638-646, 1996
Medical*Online
8) Go MF et al : Presence of the cagA gene in the majority of Helicobacter pylori strains is independent of whether the individual has duodenal ulcer or asymptomatic gastritis. Helicobacter 1 : 107-111, 1996
PubMed
9) Tomb J-F et al : The Complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 : 539-547, 1997
PubMed
10) 木村浩一ほか : ポリメラーゼ連鎖反応 (PCR) 法. Helicobacter pyloriと胃粘膜病変, 浅香正博編, 先端医学社, 東京, 1995, pp. 131-144
 
11) Enroth H et al : Immunomagnetic separation and PCR for detection of Helicobacter pylori in water and stool specimens. J Clin Microbiol 33 : 2162-2165, 1995
PubMed
12) Basso D et al : Gastric juice polymerase chain reaction. Helieobacter 1 : 159-164, 1996
 
13) 大崎敬子ほか : 免疫磁気ビーズを用いた糞便材料からのHelicobacter pyloriの検出法に関する検討. 感染症学雑誌 71 : 628-633, 1997
 
14) 黒川学ほか : 消化性潰瘍患者大便からのHelicobacter pylori検出に対するPCR法診断の有用性. 感染症学雑誌 71 : 1168-1171, 1997
 
15) Peek JRRM et al : Detection of Helicobacter pylori gene expression in human gastric mucosa. J Clin Microbiol 33 : 28-32, 1995
 
16) Amano K : Reactivities of Lewis antigen monoclonal antibodies with the eipopolysaccharides of Helicobacter pylori strains isolated from patients with gastroduodenal diseases in Japan. Clin Diagn Lab Immunol 4 : 540-544, 1997
PubMed
17) Ho S et al : Direct polymerase chain reaction test for detection of Helicobacter pylori in humans and animals. J Clin Microbiol 29 : 2543-2549, 1991
PubMed
18) Chong SKF et al : Evaluation of 16S rRNA gene PCR with primers HP1 and HP2 for detection of Helicobacter pylori. J Clin Microbiol 34 : 2728-2730, 1996
 
P.183 掲載の参考文献
1) Holton J : Clinical Relevance of Culture : Why, How, and When. Helicobacter 21S25-S33, 1997
PubMed
2) Thomas JE et al : Isolation of, Helicobacter pylori from human feces. Lancet 340 : 1194-1195, 1992
PubMed
3) Kelly SM et al : Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterotogy 107 : 1671-1674, 1994
PubMed
4) 二宮英彦ほか : Helicobacter pyloriに対する内視鏡洗浄法の検討. 日本消化器病学会雑誌 38 : 176, 1996
 
5) 伊藤武ほか : Helicobacter pyloriの生検材料よりの分離, 同定及び定量培養. 日本臨牀 51 : 3170-3175, 1993
 
6) 高橋信一ほか : 胃・十二指腸疾患におけるHelicobacter pyloriの定量的検討. Helicobacter pyloriによる胃・十二指腸粘膜障害の臨床的意義, トプコ出版, 東京, 1993, pp. 11-21
 
7) Chan WY et al : Coccoid forms of Helicobacter pylori in the human stomach. Am J Clin Pathol 102 : 503-507 1994
PubMed
8) West AP et al : Survival of Helicobacter pylori in water and saline. J Clin Pathol 43 : 609, 1990
 
P.195 掲載の参考文献
1) DiXon MF et al : Classification and grading of gastritis The Updated Sydney System. Am J of Surg Pathol 20 : 1161-1181, 1996
 
2) 太田浩良ほか : 新しい胃炎分類The Updated Sydney System. G. I. Res 5 : 493-510, 1997
Medical*Online
3) 太田浩良ほか : New Classification and Grading of Gastritis-The Updated Sydney System-. Prog Med 17 : 1610-1621, 1997
 
4) 羽山正義ほか : H. pylori感染の存在診断ならびに除菌判定病理学的診断法. Prog Med 15 : 783-790, 1995
 
5) Yabuki N et al : Analysis of cell damage and proliferation in Helicobacter pylori-infected human gastric mucosa from patients with gastric adenocarcinoma. Am J pathol 151 : 821-829, 1997
PubMed
6) Genta RM et al : Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 6 : 281-289, 1993
PubMed
7) Ota H et al : Morphological characterization of the gastric mucosa during infection with H. pylori. In : The immunology of H. pylori from pathogenesis to prevention, ed. by Emst PB et al, Lippincott-Raven, New York, 1997, pp. 15-27
 
8) 太田浩良ほか : H. pyloriと表層粘液ゲル層. 病理と臨床 13 : 1684-1688, 1995
 
9) Shimizu T et al : Immunohistochemical detection of Helicobacter pylori in the surface mucous gel layer and its clinicopathological significance. Helicobacter 1 : 197-206, 1996
PubMed
10) Shimizu T et al : Helicobacter pylori and the surface mucous gel layer of the human stomach. Helocobacter 1 : 207-218, 1996
 
11) 羽山正義ほか : カルノア固定材料を用いたHelicobacter pyloriの免疫染色学的検索方法. 病理と臨床 15, 1997
 
12) Akamatsu T et al : Histochemical Study of Helicobacter pylori and Surface mucous Gel Layer in Various Gastric Lesions. Acta Histochem et Cytochemica 28 : 181-185, 1995
 
13) Genta RM et al : Adherence of Helicobacter pylori to areas of incomplete intestinal metaplasia in the gastric mucosa. Gastroenterology 111 : 1206-1211, 1996
PubMed
14) Ota H et al : Intestinal metaplasia with adherent Helicobacter pylori : A hybrid epithelium both gastric and intestinal features. Hum Pathol 29 : 846-850, 1998
PubMed
15) Brandi G et al : Bacteria in biopsies of human hypochlorhydric stomach : a scanning electron microscopy study. Ultrastruct Pathol 20 : 203-209, 1996
PubMed
16) 鴨志田伸吾ほか : 胃生検組織におけるH. pyloriの形態学的検出とその病理学的意義. 病理と臨床 13 : 1689-1698, 1995
 
17) Gray SF et al : Simplified techniques for identifying Campylobacter pylori dis [letter]. J Clin Pathol 39 : 1279, 1986
 
18) Faulkner et al : Modified Warthin-Starry method for the demonstration of spirochetes. Stain Technol 20 : 81-82, 1945
 
19) Kerr DA : Improved Warthin-Starry method of staining spirochetes in tissue section. Am J Clin Pathol 8 : 63-67, 1938
 
20) 福島範子 : スピロヘーターの染色. 病理組織標本作成技術下巻染色法, 日本病理学会編, 医歯薬出版, 東京, 1981, pp. 158-170
 
21) Steiner G : New simple silver stain for demonstration of bacterial, spirochetes, and fungi sections from paraffin embedded tissue blocks. J Lab Clin Med 29 : 868-871, 1944
 
22) Genta RM et al : Simultaneous visualization of Heticobacter pylori and gastric morphology : a new stain. Hum Pathol 25 : 221-226, 1994
PubMed
23) 岩木宏之ほか : Helicobacter pylori (Hp) の新しい組織染色法の開発とその染色法のコツ. 病理技術 54 : 29-31, 1996
 
24) 大場祥ほか : 組織切片におけるHelocobacter pyloriの検出法に関する研究-ヒメネス染色変法-. 病理と臨床 16 : 105-107, 1998
 
25) Walters LL et al : Acridine-orange to identify Campylobacter pylori dis in formalin fixed, paraffin-embedded gastric biopsies [letter]. Lancet i : 42, 1986
 
P.202 掲載の参考文献
1) Graham DY et al : Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet 1 : 1174-1177, 1987
 
2) Ferrero RI et at : The urease enzyrnes of Campylobacter pylori and a related bacterium. J Med Microbiol 27 : 33-40, 1988
 
3) 谷口友志ほか : 13C-尿素呼気試験法. Helicobacter pyloriの最新知見, 日本消化器病学会編, 中山書店, 東京, 1995, pp. 181-186
 
4) Shuichi Ohara et al : Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. Journal of Gastroenterology 33 : 6-13, 1998
 
5) Logan RPH et al : The Europian 13C-urea breath test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 3 : 915-921, 1991
 
6) Eggers RH et al : A methodological analysis of the 13C-urea breath test for detection of, Helicobacter pylori infection : high sensitivity and specificity within 30 min using 75mg of 13C-urea Eur J Gastroenterol Hepatol 2 : 437-444, 1990
 
7) 大原秀一ほか : Helicobacter pylori感染診断における13C-尿素呼気試験法の検討. 日本消化器病学会雑誌 93 : 530-536, 1996
Medical*Online
8) 加藤元嗣ほか : Helicobacter pylori感染診断法, 13C-尿素呼気試験に及ぼす影響因子. 新薬と臨床 45 : 2157-2165, 1996
 
9) Marshall BJ et al : A 20-minute breath test for Helicobacter pylori. Am J Gastroenterol 86 : 438-445, 1991
PubMed
10) Logan RPH et al : Simplified single sample 13Carbon urea breath test for Helicobacter pylori : comparison with histology, culture, and ELIZA serology. Gut 32 : 1461-1464, 1991
 
11) Klein PD et al : Minimum analysis requirements for the detection of Helicobacter pylori infection by the 13C-urea breath test. Am J Gastroenterol 88 : 1865-1869, 1993
PubMed
12) Klein PD et al : Noninvasive detection of Helicobαcter pylori infection in clinical practice : The 13C-urea breath test. Am J Gastroenterol 91 : 690-694, 1996
 
13) Shuichi Ohara et al : The UBiT-100 13CO2 infrared analyzer : Comparison between infrared spectrometric analysis and mass spectrometric analysis. Helicobacter 3 : 49-53, 1998
 

第8章 治療

P.211 掲載の参考文献
1) NIH Consensus Conference : Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272 : 65-69, 1994
 
2) The European Heticobacter pylori Study Group : Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41 : 8-13, 1997
 
3) Helicobacter Pylori治験検討委員会 : HP治験ガイドライン. 日本消化器病学会, 1995
 
4) Marshall BJ et al : Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet i : 1437-1442, 1988
PubMed
5) Rauws EAI et al : Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet ii : 1233-1235, 1990
 
6) Miehlke S et al : Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 7 : 975-978, 1995
PubMed
7) Sung JJY et al : Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 332 : 139-142, 1995
 
8) Hulst RWMVD et al : Prevention of ulcer recurrence after eradication of Helicobacter pylori : a prospective long-term follow-up study. Gastroenterology 113 : 1082-1086, 1997
PubMed
9) Avsar E et al : Refractory duodenal healing and reapse : comparison of omeprazole with Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 8 : 449-452, 1996
 
10) Kodama R et al : Helicobacter pylori infection delays the healing of acetic acid induced gastric ulcer in Japanese monkeys. J Gastroenterol Hepatol 11 : 1097-1102, 1996
PubMed
11) Isaacson PG et al : Malignant lymphoma of mucosa associated lymphoid tissue. Cancer 52 : 1410-1416, 1983
 
12) Bayerdortifer E et al : Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of, Helicobacter pylori infection. Lancet 345 : 1591-1594, 1995
 
13) Roggero E et al : Eradication of Helicobacter pylori infection in primary low grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122 : 767-769, 1995
PubMed
14) Cammarota G et al : Prevention and treatment of low grade B cell primary gastric lymphomz by anti H. pylori therapy. J Clin Gastroenterol 21 : 118-122, 1995
PubMed
15) Montalban C et al : Treatment of low grade gastric MALT lymphoma with Helicobacter pylori eradication. Lancet 345 : 798-799, 1995
PubMed
16) Cammarota G et al : Helicobacter pylori reinfection and rapid relapse of low-grade B-cell gastric lymphoma. Lancet 345 : 192, 1995
PubMed
17) International agency for research on cancer : Schistosome, liver flukes and Helicobacter pylori. IARC Monogr. Eval. Carcinog. Risks Hum 61 : 177-241, 1994
 
18) Davies GR et al : Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 35 : 179-185, 1994
PubMed
19) Lynch DAF et at : Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy. Gut 36 : 346-350, 1995
 
20) Banerjee S et al : Effect fo Helicobacter pytori and its eradication on gastric juice ascorbic acid. Gut 35 : 317-322, 1994
 
21) Correa P : Human gastric carcinogenesis : a multistep and multifactorial process-first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52 : 6735-6740, 1992
PubMed
22) Shuto R et al : Experimental gastritis induced by Helicobacter pylori in Japanese monkeys. Infect Immun 61 : 933-939, 1993
PubMed
23) Fujioka T et al : Experimental model for chronic gastritis with, Helicobacter pylori : long-term follow-up study in H. pylori-infected Japanese macawues. Eur J Gastroenterol Hepatol 5 (suppl.) : 73-77, 1993
 
24) S. Honda et al : Gastric ulcer, atrophic gastritis, and intestinal metaplasia casused by Helicobacter pylori infection in Mongolian gerbils. Scand J Gastroenterol 33 : 454-460, 1998
 
25) Uemura N et al : Effect of Helicobacter pylori eradication inhibits on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarfeers Prev 6 : 639-642, 1997
 
26) 斉藤大三ほか : 厚生科学研究補助金・がん克服10ヵ年戦略研究事業, Helicobacter pylori感染の早期発見とその除菌による胃がんの予防に関する研究, プロトコールの紹介. カレントテラピー 14 : 1819-1824, 1996
 
27) Borody TJ et al : Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. Am J Gastroenterol 88 : 1266-1268, 1993
PubMed
28) Witteman EM et al : Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori. J Clin Pathol 48 : 250-256, 1995
PubMed
29) Jaskiewicz K et al : Long-term histological consequences of suppression/eradication of Helicobacter pylori in antral mucosa. Eur J Gastroenterol Hepatol 5 : 701-705, 1993
 
30) Chan FKL : Randomised trial of eradication of Helicobacter pylori before non-steroid anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350 : 975-979, 1997
 
31) Bianchi PG : Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long term NSAID ulcers. Response to omeprazole dual therapy. Gut 39 : 22-26, 1997
 
32) Helicobacter pylori治験検討委員会 : HP治験ガイドライン. 日本消化器病学会雑誌 96 : 199-207, 1999
 
P.222 掲載の参考文献
1) Warren JR et al : Unidenthied curved bacilli on gastric epithelium in active chronic gastritis. Lancet i : 1273-1275, 1983
PubMed
2) 杉山敏郎 : Helicobacter pyloriの菌種と消化性潰瘍. Med Pract 13 : 1845-1848, 1996
Medical*Online
3) Labenz JB et al : Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 : 1442-1447, 1997
 
4) 加藤元嗣ほか : H. pylori除菌後に生じる上部消化管疾患. 消化器科 26 : 502-506, 1998
 
5) Tytgut GNJ : Helicobacter pylori : causal agent in peptic ulcer disease? In : Working Party Report of the World Congress of Gastroenterology, Blackwell Scientific Publication, Oxford, 1990, pp. 36-45
 
6) NIH consensus. Helicobacter pylori in peptic ulcer disease. JAMA 272 : 65-69, 1994
 
7) Soll AH : Consensus conference. medical treatment of peptic ulcer disease. practice guidelines. JAMA 275 : 622-629, 1996
PubMed
8) Malfertheiner P et al : Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus. Eur J Gastroenterol Hepatol 9 : 1-2, 1997
PubMed
9) Uemura N et al : Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6 : 639-642, 1997
PubMed
10) Sugiyama A et al : Helicobacter pylori infection enhances N-Methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian Gerbil. Cancer Res 58 : 2067-2069, 1998
PubMed
11) Peura DA : The report of the Digestive Helth initiativeSM international update conference on Helicobacter pylori. Gastroenterology 113 : S4-8, 1997
 
12) Lam SK et al : Report of the 1997 asia pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13 : 1-12, 1998
 
13) 青山伸郎 : 神戸ワークショップによるわが国の動向. Helicobacter Res 2 : 39-47, 1998
Medical*Online
14) Chiba N et al : Meta-analysis of the efficacy of antibiotics therapy in eradicating Helicobacter pylori. Am J Gastroenterol 87 : 1716-27, 1992
PubMed
15) Hulst RWM et al : Treatment of Helicobacter pylori infection : A review of the world literatUre. Helicobacter 1 : 6-19, 1996
 
16) 木村健ほか : Lansoprazole/amoxicillin 2剤併用によるHelicobacter pylori除菌療法の全国多施設第2相試験. 第4回日本ヘリコバクター学会抄録集, 1998, p73
 
17) Kato M et al : Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori infected gastric ulcer patients. Dig Dis Sci 43 : S198-202, 1998
 
18) 加藤元嗣ほか : 日本独自の除菌治療法を求めて. 消化器内視鏡 8 : 661-667, 1996
 
19) Pipkin GA et al : Clarithromycin dual therapy regimens for eradication of eradication Helicobacter pylori : A review. Helicobacter 2 : 159-171, 1997
PubMed
20) Bazzoli F et al : Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 6 : 773-777, 1994
 
21) Lind T et al : Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobails : The MACH-1 study. Helicobacter 1 : 138-144, 1996
PubMed
22) Kimura K et al : A 1-h topical therapy for the treatment of the Helicobacter pylori infection. Am J Gastroenterol 90 : 60-63, 1995
 
23) Nagata K et al : Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori : unique action selective for H. pylori cells. Antimicrob Agentsohemother 37 : 769-774, 1993
PubMed
24) Mauch I et al : Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 88 : 1801-1802, 1993
 
25) Iwai T et al : Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 35 : 490-496, 1991
 
26) 藤岡利生ほか : PPIの抗Helicobacter py;ori活性と除菌治療への応用. Helicobacter pyloriの最新知見, 日本消化器病学会編, 中山書店, 東京, 1995, pp. 279-286
 
27) 平井雅道ほか : プロトンポンプ阻害剤とHelicobacter pylori-基礎-. プロトンポンプインヒビター-21世紀への展望-, 竹本忠良ほか監修, メディカルレビュー社. 東京, 1998, pp. 122-129
 
28) Axon ATR : The role of omeprazole and antibiotc combinations in the eradication of Helicobacter pylori-An update. Scand J Gastroenterol 29 (Suppl.) : 31-37, 1994
 
29) Miehlke S et al : An increasing dose of omeprazole combined with amoxycillin cures, Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1 1 : 323-329, 1997
 
30) Murakami K et al : Effects of New triple therapy regimens on inhibition of gastric acid secretion and eradication of Helicobacter pylori in a randomized trial. (submitted) (提出中)
 
31) 加藤元嗣ほか : H. pylori除菌療法における酸分泌抑制剤の効果. 消化器研究の新たな進歩VOL. 2, 松尾裕監修, ヴァンメディカル, 東京, 1997, pp. 29-32
 
32) 加藤元嗣ほか : 耐性菌の出現とその対策. Helicobacter Res 1 : 459-465, 1997
Medical*Online
33) 佐藤竜吾ほか : 初回治療に失敗したらどうするか. ヘリコバクター・ピロリ除菌治療ハンドブック, 藤岡利生ほか編, 医学書院, 東京, 1997, pp. 85-91
 
34) Xia HX et al : Effects of antibiotic-resistance on clarithromycin combined triple therapy for Helicobacter pylori. Gut 37 (Suppl. 1) : A55, 1995
 
35) Yousfi MM et al : Metronidazole, omeprazole and clarithromycin : an effective combination therapy for Helicobacter pylori infection. Aliment, Phamacol Ther 9 : 209-212, 1995
 
36) Moayyedi P et al : Efficacy and optimum dose of omeprazole in a new 1-week triple therapy. Eur J Gastroenterol Hepatol 7 : 835-840, 1995
 
37) de Boer WA : How to treat Heliobacter pylori infection-should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol 8 : 709-716, 1996
 
38) Tytgat GNJ et al : Important acquisitions in Helicobacter pylori infection. Curr Opin Gastroenterology 11 (suppl.) : 57-60, 1995
 
P.229 掲載の参考文献
1) 吉成昌朗ほか : オメプラール錠. Pharm Med 9 : 165-176, 1991
 
2) 藤岡利生ほか : Helicobacter pyloriに対する各種薬剤の抗菌力と除菌率. 日本臨牀 51 : 3255-3260, 1993
Medical*Online
3) 横田好子ほか : Helicobacter pyloriに対するCefdinirおよびOmeprazoleの抗菌力とウレアーゼ阻害作用の相関. 感染症学雑誌 67 : 808-815, 1993
 
4) Greig MA et al : Harnessing of urease activity of Helicobacter pylori to induce self-destruction of the bactrium. J Clin Pathol 44 : 157-159, 1991
 
5) Meyer-rosberg K et al : The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 111 : 886-900, 1996
PubMed
6) Mauch I et al : Identhication and characterization of an ATPase system of Heicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 88 : 1801-1802, 1993
 
7) Wilde MI et al : Omeprazole. An update of its pharmacology and threpeutic use in acid-related disorders. Drugs 48, 91-132, 1994
PubMed
8) Louw JA et al : Omeprazole may clear but dose not eradicate H. pylori. Eur J Gastroenterol Hepatol 4 : 481-485, 1992
 
9) 佐藤貴一ほか : Dual therapy (2剤併用療法). Med pract 13 : 1901-1910, 1996
 
10) Lain L et al : Limited efficacy of Omeprazole-based dual and triple therapy for Helieobacter pylori : a randomized trial employing "optimal" dosing. Am J Gastroen terol 90 : 1407-1410, 1995
 
11) Mohammad TA et al : Treatment of Helicobacter pylori infection with Omeprazole-Amoxicillin combination therapy versus Ranitidine/Sodium Bicarbonate-Amoxicillin. Am J Gastroenterol 90 : 1411-1414, 1995
 
12) Kathleen SG et al : Variability with Omeprazole-Amoxicillin combinations for treatment of Helicobacter pylori infection. Am J Gastroenterol 90 : 1415-1418, 1995
 
13) Saberi-Firoozi M et al : Effect of triple therapy or Amoxicillin plus Omeprazole or Amoxicillin plus Tinidazole plus Omeprazole on duodenal ulcer healing, eradication of Heticobacter pylori, and prevention of ulcer relapse over a 1-year follow-up Period : a prospective, randomized, controlled study. Am J Gastroenterol 90 : 1419-1423, 1995
 
14) Malaty HM et al : High dose PPI plus amoxicillin for treatment of Helicobacter pylori infection. Gastroenterology 110 : A184, 1996
 
15) Graham AP et al : Clarithromycin dual therapy regimens for eradicaton of Helicobacter pylori : a review. Helicobacter 2 : 59-171, 1997
 
16) Gustavson LE et al : Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 39 : 2078-2083, 1995
PubMed
17) Lind T et al : Eradication of Helicobacter pylori using one-week triple therapies combining Omeprazole with two antimicrobials : the MACH-1 study. Helicobacter 1 : 138-144, 1996
PubMed
18) Lind T et al : The MACH-2 study optimal Helicobacter pylori therapy needs Omeprazole and can be reliably assessed by UBT. Gastroenterology 112 : A200, 1997
 
P.237 掲載の参考文献
1) 木平健ほか : プロトンポンプ阻害剤AG-1749 (Lansoprazole) の胃内pHに対する影響の検討-24時間胃内pHモニタリング試験-. 日本消化器病学会雑誌 88 : 672-680, 1991
 
2) J Gerloff et al : Pharmacokinetics and absolute bioavailability of lansoprazole. EurJ, Pharmacol 50 : 293-297, 1996
 
3) Bell NJ et al : Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharvazacol Ther 10 : 897-904, 1996
PubMed
4) Masafumi Nakao et al : Growth Inhibitory and Bactericidal Activities of lansoprazole Compared with Those of Omeprazole and Pantoprazole against Helicobacter pylori. Heticobacter 3 : 21-27, 1998
 
5) Masafumi Nakao : Antibacterial Properties of Lansoprazole Alone and in Combination with Antimicrobial Agents Against/Helicobacter pylori. J Clin Gastroenterol 20 (suppl. 1) : S32-S37, 1995
 
6) PDMidolo et al : Bactericidal activity and synergy stUdies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J Antimicrob Chemother 39 : 331-337, 1997
PubMed
7) Sunao Kawano et al : Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. J Gastroenterol 31 (suppl. IX) : 41-43, 1996
 
8) Cayla R et al : Essai Controle Ramdomise Comparant la Bitherapie (Lansoprazole a forte dose-Amoxicilline-Clarithromycine) Dans L'infection a Helicobacter pylori (H. p). Gastroenterol Clin Biol 19 : A89, 1995
 
9) H Schwartz et al : Triple Versus Dual Therapy for Eradication Helicobacter pylori and Preventing Ulcer Recurrence : A Randomized, Double-Blind, Multicenter Study of Lansoprazole, Clarithromycin, and/or Amoxicillin in Different Dosing Regimens. Am J Gastroenterol 93 : 584-590, 1998
PubMed
10) Paul Moayyedi et al : Comparison of One or Two Weeks of Lansoprazole, Amoxicillin, and Clarithromycin in tle Treatment of, Helicobacter pylori. Helicobacter 1 : 71-74, 1996
 
11) 大原正志ほか : 酸分泌抑制剤の免疫制御作用-Lansoprazole Weekend Therapyの有用性と効果背景-. 消化器研究の新たな進歩 VOL. 2, 松尾裕監修, ヴァンメディカル, 東京, 1997, pp. 37-41
 
P.242 掲載の参考文献
1) Warren JR, Marshall BJ : Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i : 1273-1275, 1983
 
2) Graham DY et al : Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med 116 : 705-708, 1992
PubMed
3) Kuipers EJ et al : Long-term sequelae of, Helicobacter pylori gastritis. Lancet 345 : 1525-1528, 1995
PubMed
4) Craanen ME et al : Intestinal metaplasia and Helicobacter pylori. An endoscopic bioptic study of the gastric antrum. Gut 33 : 16-20, 1992
PubMed
5) Cabtree JE et al : Interleukin-8 expression in Helicobacter pylori infected, normal and neoplastic gastroduodenal mucosa. J Clin Pathol 47 : 61, 1994
 
6) Tummuru MK et al : Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol 18 : 867-876, 1995
PubMed
7) Davies GR et al : Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 35 : 179-185, 1994
PubMed
8) Tomb J-F et al : The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 : 539-547, 1997
PubMed
9) 殿村英郎ほか : Helicobacter pyloriに対するラベプラゾールの作用. Helicobacter pyloriと胃粘膜病変, 浅香正博編, 先端医学社, 東京, 1995, pp. 183-188
 
10) Hirai M et al : A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 30 : 461-464, 1995
PubMed
11) Mauch I et al : Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 88 : 1801-1802, 1993
 
12) Tsuchiya M et al : Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 18 : 1053-1056, 1995
PubMed
13) Park J-B et al : Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 19 : 182-187, 1996
 
14) Scott DR et al : The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 114 : 58-70, 1998
PubMed
15) Stack WA et al : Rabeprazole is effective and safe when used in combination with antibiotics for the eradication of Helicobacter pylori. Gut 41 (suppl. 3) : 740, 1997
 
16) 山本達男 : 運動性および走化性-特集Helicobacter pylori胃粘膜傷害機序研究の最前線-, Helicobacter Res 1 : 341-348, 1997
 
P.247 掲載の参考文献
1) 長手尊俊ほか : Campylobacter pyloriの薬剤感受性. 最新医学 44 : 318-322, 1989
Medical*Online
2) 久保田利博ほか : Helicobacter pyloriの治療. Medico 25 : 10928-10931, 1994
 
3) 勝山努ほか : 臨床材料由来Helicobcter pyloriの各種薬剤に対する最小発育阻止濃度. Helicobacter Pylori治験ガイドライン資料, Helicobacter pylori治験検討委員会編, 日本消化器病学会, 東京, 1995, pp. 8-9
 
4) 井本一郎ほか : わが国におけるHelicobacter pylori除菌療法. Helicobacter Res 1 : 31-36, 1997
Medical*Online
5) 藤岡利生 : 各種抗菌薬の特徴. カレントテラピー 14 : 1780-1784, 1996
 
6) 榊信廣 : Helicobacter pylori除菌療法における胃粘膜防御剤併用の意義. Pharm Med 14 : 135-142, 1997
 
7) Snnairi M et al : Effect of anti-ulceragents on activities of antibiotics against Helicobacter pytori. Eur J Gastroenterol Hepatol 6 (suppl. 1) : 121-124, 1994
 
8) 神谷茂ほか : Helicobacter pyloriの空胞化毒素産生に及ぼすソファルコンの効果. Prog Med 15 : 2383-2388, 1995
Medical*Online
P.250 掲載の参考文献
1) Labenz J et al : Intragastric acidity as a predictor of the success of Helicobacter pylori eradication : a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 37 : 39-43, 1995
PubMed
2) Adamek RJ et al : Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptic ulcer bleeding. Scand J Gastroenterol 29 : 880-883, 1994
PubMed
3) van Zanten SJO et al : Secretion of intravenously administered antibiotics in gastric juice : implications for management of, Helicobacter pylori. 1 Clin Pathol 45 : 225-227, 1992
 
4) Adamek RJ et al : Successful Helicobacter pylori eradication : a systemic effect of antibiotics? Am J Gastroenterol 88 : 792-793, 1993
PubMed
5) Labenz J et al : Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Scand J Gastroenterol 29 : 1070-1075, 1994
PubMed
6) Atherton JC et al : Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxicillin and cimetidine. Gut 36 : 670-674, 1995
PubMed
7) Suzuki M et al : Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori : Effect of Sofalcone. J Clin Gastroenterol 27 (Suppl. 1) : 183-186, 1998
 
8) Bayerdorffer E et al : Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108 : 1412-1417, 1995
PubMed
9) 鈴木紘一ほか : 抗生物質腸炎の糞便細菌叢. 最新医学 38 : 2481-2489, 1983
Medical*Online
P.256 掲載の参考文献
1) Tytgat GNJ et al : Helicobacter pylori : causal agent in peptic ulcer disease. In : Working party reports of the world congresses of Gastroenterology, Blackwell Scientific Pub, Melbourne, 1990, pp. 36-45
 
2) NIH consensus : Helicobacter pylori in peptic ulcer disease. JAMA 272 : 65-69, 1994
 
3) Malfertheiner P et al : Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus. Eur J Gastroenterol Hepatol 9 : 1-2, 1997
PubMed
4) Cosar C et al : Activity of (hydroxy-2'Ethyl) -1 methyl-2 nitro-5 imidazole (8.823 R. P.) in experimental Trichomonas vaginalis infections. Ann Inst Pasteur 96 : 238-241, 1959
 
5) Durel P et al : Flagyl (Metronidazole). Br J Vener Dis 36 : 154, 1960
PubMed
6) 佐藤竜吾ほか : 初回治療に失敗したらどうするか. ヘリコバクター・ピロリ除菌治療ハンドブック, 藤岡利生ほか編, 医学書院, 東京, 1997, pp. 85-91
 
7) Bazzoli F et al : Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol, Hepatol 6 : 773-777, 1994
 
8) Megraud F et al : Treatment of Helicobacter pylori infection : summary of a meeting at the Fourth United European Gastroenterology Week. Helicobacter 1 : 118-121, 1996
PubMed
9) Lind T et al : Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials : The MACH-1 Study. Helicobacter 1 : 138-144, 1996
PubMed
10) Pieramico O et al : Omeprazolebased dual and triple therapy for the eradication of H. P妙lori i nfection in peptic ulcer disease : a randomized trial. Gastroenterology 110 : A229, 1996
 
11) Goh KL et al : Omeprazole 40mg o. m. combined with amoxicillin alone or with amoxicillin and metronidazole in the eradication of, Helicobacter pylori. Am J Gastroenterol 89 : 1789-1792, 1994
PubMed
12) Bell GD et al : Addition of metronidazole to omeprazole/amoxicillin dual therapy increases the rate of Helicobacter pylori eradication : a doudle-blind, randomized trial. Aliment Pharmacol Ther 9 : 513-520, 1995
 
13) Lamouliatte H et al : Effect of lansoprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori : a randomized, double blind, multicentre study. Gastroenterology 110 : A170, 1996
 
14) Labenz J et al : One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 7 : 9-11, 1995
PubMed
15) Pryce DI et al : One week of lansoprazole, clarithromycin & metronidazole eradicates Helicobacter pylori. Gastroenterology 110 : A235, 1996
 
16) Schwartz H et al : Seven-day triple therapy with lansoprazole, clarithromycin and metronidazole for the cure of Helicobacter pylori infection ; a short report. Helicobacter 1 : 251-255, 1996
 
17) Beard CM et al : Cancer after exposure to metronidazole. Mayo Clin Proc 63 : 147-153, 1988
PubMed
18) Megraud F : H. pylori existence to antibiotics. In : Helicobacter pylori basic Mechanisms to clinical cure, Kluwer Academic Publishers, London, 1993, pp. 570-583
 
19) 青山伸郎ほか : 消化性潰瘍治療におけるHp除菌療法の問題点. 消化器科 23 : 36-44, 1996
 
20) 宮地英生ほか : 薬剤耐性Helicobacter pyloriの検討. 日本消化器病学会雑誌 93 : 274, 1996
 
21) 福田能啓ほか : ヘリコバクター・ピロリ除菌治療に用いられる薬剤. ヘリコバクター・ピロリ除菌治療ハンドブック, 藤岡利生ほか編, 医学書院, 東京, 1997, pp. 21-42
 
22) 加藤元嗣ほか : 耐性菌の出現とその対策. Helicobacter Res 1 : 459-465, 1997
Medical*Online
23) Thomas KWL et al : An increase in Helicobacter pylori strains resistant to metronidazole : A five-year study. Helicobacter 1 : 57-61, 1996
 
24) Xia HX et al : Effects of antibiotic-resistance on clarithromycin combined triple therapy for Helicobacter pylori. Gut 37 : A55, 1995
 
25) Yousfi MM et al : Metronidazole, omeprazole and clarithromycin : an effective combination therapy for Helicobacter pylori infection. Aliment Phamaacol Ther 9 : 209-212, 1995
PubMed
26) Moayyedi P et al : Efficacy and optimum dose of omeprazole in a new 1-week triple therapy. Eur J Gastroenterol 7 : 835-840, 1995
 
27) 加藤元嗣ほか : 日本独自の除菌治療法を求めて. 消化器内視鏡 8 : 661-667, 1996
 
28) Borody TJ et al : Eradication failure after H. pylori treatment-further therapies. Gastroenterology 110 : A67, 1996
 
P.263 掲載の参考文献
1) Koga T et al : In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori. J Antimicrob Chemother 37 : 919-929, 1996
PubMed
2) Takagi A et al : Suppression of H. pylori -induced IL-8 secretion by an anti-ulcer agent, plaunotol in vitro. Gastroenterology 110 (suppl. 4) : A269, 1996
 
3) 古賀哲文ほか : プラウノトールのHelicobacter pyloriに対するin vitroおよびin vivo効果. Helicobacter pyloriと胃粘膜病変, 先端医学社, 東京, 1995, pp. 202-208
 
4) 駒井亨ほか : ラットおよびイヌにおけるPlaunotolの吸収・分布・排泄・代謝. Prog Med 5 (suppl. 1) : 849-862, 1985
 
5) Galbraith H et al : Antibacterial activity of long chain fatty acids and reversal with calcium, magnesium, ergocalciferol and cholesterol. J Appl Bacteriol 34 : 803-813, 1971
PubMed
6) Kondo E et al : The relationship between the chemical structure of fatty acids and their mycobactericidal activity. Jap J Med Sci Biol 30 : 171-178, 1977
PubMed
7) Lien EJ et al : Structure-activity correlations for antibacterial agents on gram-positive and gram-negative cells. J Med Chem 11 : 430-441, 1968
 
8) Koga T et al : Bactericidal effect of plaunotol, a cytoprotective antiulcer agent, against Helicobαcter pylori. J Antimicrob Chemother 38 : 387-397, 1996
 
9) Greenway DL et al : Mechanism of the inhibitory action of linoleic acid on the growth of Staphylococcus aureus. J Gen Microbiol 115 : 233-245, 1979
PubMed
10) Koga T et al : Interactions of plaunotol with bacterial membrane. J Antimicrob Chemother 42 : 133-140, 1998
PubMed
11) Smith MA et al : Radox potential and oxrygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. J Antimicrobohemother 35 : 751-764, 1995
 
P.273 掲載の参考文献
1) Moran AP et al : Pathogenic Propenies of Helicobacter pylori. Scand J Gastroenterol 31 (suppl. 215) : 22-33, 1996
 
2) Mobley HLT et al : Helicobacter pylori Factors Associated With Disease Development. Gastroenterology 113 (suppl.) : S21-28, 1997
 
3) Smoot DT et al : How Dose Helicobacter pylori Cause Mucosal Damage ? Direct Mechanisms. Gastroenterology 113 (suppl.) S31-34, 1997
 
4) Ernst PB et al : How Dose Helicobacter pylori Cause Mucosal Damage? The Inflammatory Response. Gastroenterology 113 (suppl.) S35-42, 1997
 
5) Crabtree JE et al : Mucosal tumor necrosis factorα and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 32 : 1473-1477, 1991
 
6) KarttUnen R et al : Interferon gamma and interleukin 4 secreeting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 36 : 341-345, 1996
 
7) D'Elios MM et al : Dfferent cytokine profile and antigen-spechicity repertoire in Helicobacter pylori -specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol 27 : 1751-1755, 1997
PubMed
8) D'Elios MM et al : T Helper Effector Cells Spechic for Helicobacter pylori in the Gastric Antum of Patients with Peptic Ulcer Disease. J Immunol 158 : 962-967, 1997
 
9) Kleine A et al : Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38 : 1441-1449, 1993
PubMed
10) 石山広信ほか : Proamide (OPC-12759) の胃粘液分泌に対する作用. 薬理と治療 16 : 4103-4109, 1998
 
11) 川野淳ほか : Rebamipide (OPC-12759) のラットおよびヒト胃粘膜防御作用についての検討. 日本薬理学雑誌 97 : 371-380, 1991
Medical*Online
12) Yoshikawa T et al : Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indomethacin in rats. Arzneimittelforschung 43 : 1327-1330, 1993
PubMed
13) Aihara M et al : Mechanisms Involved in Helicobacter pylori-Induced lnterleukin-8 Production by a Gastric Cancer Cell Line, MKN45. Infection and Immundy 65 : 3218-3224, 1997
 
14) Aihara M et al : Molecular Analysis of the Suppression of lnterleukin-8 Production by Rebamipide in Helicobacterpylori Stimulated Gastric Cancer Cell Lines. Dig Dis Sci (suppl.) 43 (9) : 1745-1805, 1998
 
15) Aihara M et al : Effects of Rebamipide on the Production of Several Cytokines by Human Peripheral Blood Mononuclear Cells. Dig Dis Sci (suppl.) 43 (9) : 1605-1665, 1998
 
16) Nagano C et al : IFN-γ-lnduced iNOS mRNA Expression ls lnhibited by Rebamipide in Murine Macrophage RAW264. 7 Cells. Dig Dis Sci (suppl.) 43 (9) : 1185-1245, 1998
 
17) Mukaida N et al : Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol 56 : 554-558, 1994
PubMed
18) Keates S et al : Helicobacter pylori Infection Activates NF-κB in Gastric Eipthelial Cells. Gastroenterology 113 : 1099-1109, 1997
 
19) Modlin RL et al : Th1-Th2 paradigm : insights from leprosy. J Invest Dermatol 102 : 828-832, 1994
PubMed
20) Clerici M et a1 : The Th1-Th2 hypothesis of HIV infection ; new insights. Immunol Today 15 : 575-581, 1994
 
21) Bamiord KB et al : Lymphocytes in the Human Gastric Mucosa During Helicobacter pylori Have a T Helper Cell 1 Phenotype. Gastroenterology 114 : 482-492, 1998
 
22) Haeberle HA et al : Dfierential Stimulaions of lnterleukin 12 (IL-12) and IL-10 by Live and Klled Helicobacter pylori In Vitro and Association of IL-12 Production With Gamma Interferon-Producing Cells in the Human Gastric Mucosa. Infection and Immunity 65 : 4229-4235, 1997
 
23) Mohammadi M et al : Murine CD4 T-Cell Response to Helicobacter pylori : TH1 Cell Enhance Gastritis and TH2 Cells Reduce Bacterial Load. Gastroenterology 1131848-1857, 1997
 
24) Mohammadi M et al : Helicobacter-Specific Cell-Mediated Immune Responses Display a Predominant Th1 Phenotype and Promote a Delayed-Type Hypersensitivity Response in the Stomachs of Mice. J Immunol 156 : 4729-4738, 1996
PubMed
25) Fan XG et at : Cytokine production in patients with H. pylori infection. Ir J Med Sci 163 : 582, 1994
 
26) Fan XG et al : Enhamced T-helper 2 Lymphocyte Responses : Immune Mechanism of Helicobacter pylori Infection. (Minireview). Ir J Med Sci 165 : 37-39, 1996
 
27) Fan XG et al : Effect of IL-4 on peripheral blood lymphocyte proliferation : implication in immunopathogenesis of H. pylori infection. Immunol Lett 48 : 45-48, 1995
PubMed
28) Fan XJ et al : Gastric T lymphocyte response to Helicobacter pylori in patients with H. pylori colonisation. Gut 35 : 1379-1384, 1994
 
29) Cenci E et al : T Helper Cell Type 1 (Th1) -and Th2-like Responses Are Present in Mice with Gastric Candidiasis but Protective Immunity Is Associated with Th1 Development. J Infec Dis 171 : 1279-1288, 1995
 
30) Bistoni F et al : Neutralization of IL-10 Up-Regulate Nitric Oxide Production and Protects Susceptible Mice from Challenge with Candida albicans. J Immunol 152 : 3514-3521, 1994
 
31) Koshland DE Jr : The Molecule of the Year. Science 258 : 1861, 1992
PubMed
32) Culotta E et at : NO News Is Good News. Science 258 : 1862-1865, 1992
 
33) Nathan C : Nitric oxide as a secretary product of mammalian cells. FASEB J 6 : 3051-3064, 1992
 
34) Petros A et al : Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338 : 1557-1558, 1991
PubMed
35) Desai KM et al : Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 351 : 477-479, 1991
PubMed
36) Desai KM et al : Nitroxergic nerves mediate vagally induced relaxation in the isolated stomach of the guinea pig. Proc Natl Acad Sci USA 88 : 11490-11494, 1991
PubMed
37) Bogdan C et al : Of microbes, macrophages and nitric oxide. Behring Inst Mitt 99 : 58-72, 1997
PubMed
38) Bogdan C et al : Invasion, control and persistence of Leishmania parasites. Curr Opin Immunol 8 : 517-525, 1996
PubMed
39) Mannick EE et al : Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis : effect of antibiotics and antioxidants. Cancer Res 56 : 3238-3243, 1996
PubMed
40) Page CL et al : Inhibitors' of ADP-Ribosylation Impair Inducible Nitric Oxide Synthase Gene Transcription through Inhibition of NF Kappa B Activation. Biochem Biophys Res Commun 243 : 451-457, 1998
 
P.282 掲載の参考文献
1) 松澤賢治ほか : Helicobacter pylori 感染と表層粘液ゲル層. G. I. Res 2 : 31-36, 1994
Medical*Online
2) 田辺製薬社内資料
 
3) Ito Y et al : Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Eur J Pharmacol 345 : 193-198, 1998
PubMed
4) Ito Y et al : Mechanism of anti-urease action by the anti-ulcer drug ecabet sodium. Biol Pharm Bull 16 : 850-853, 1995
 
5) Shibata k et at : Bactericidal activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Antimicrob Agents Chemother 39 : 1295-1299, 1995
 
6) 田辺製薬社内資料
 
7) 田辺製薬社内資料
 
8) 加藤元嗣ほか : 耐性菌の出現とその対策Helicobacter Res 1 : 459-465, 1997
 
9) Miyaji M et al : The prevalence of the drug resistance in」Helicobacter pylori and the effects of the resistance on the eradication therapy in Japan. Gastroenterot 112 (suppl.) : A222, 1997
 
10) Shibata K et al : Bactericidal effect of ecabet sodium on clarithromycin-and metronidazole-resistant clinical isolates of Helicobacter pylori. Jpn J Antibiot 50 : 525-531, 1997
PubMed
11) Bode G et al : The coccoid forms of Helicobacter pylori. Criteria for their viability. Epidemiol Infect 111 : 483-490, 1993
PubMed
12) 芝田和夫, 松下忠弘 : Helicobacter pyloriのcoccoid formに対する胃炎・胃潰瘍治療薬エカベトナトリウムの作用. Jpn J Chemother 45 : 394, 1997
 
13) Masubuchi N et al : Effects of ecabet sodium (TA-2711) and benzohydroxamic acid (BHA) on Helicobacter pylori infection in the cynomolgus monkeys. Am J Gastroenterol 89 : 1381, 1994
 
14) Hayashi S et al : Effect of ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. J Gastroenterol 32 : 593-597, 1997
PubMed
15) Fukuda Y et al : Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer padents. J Clin Gastroenterol 20 (suppl. 2) : S132-135, 1995
 
16) Shimoyama T et al : Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastoenterol 31 (suppl. 6) : 59-62, 1996
 
17) Ohkusa T et al 1Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection. Aliment Phamacol Ther 12 : 457-461, 1998
 
18) Kagaya H et al : Study on the effect of a new anti-ulcer agent, ecabet sodium, on the dual therapy for eradication of Helicobacter pylori in randomized patients. Gastroenterol 114 : A164, 1998
 
19) Matsukura N et al : Two step therapy for H. pylori eradication with lansoprazole, amoxicillin and a mucosal protective agent ecabet sodium. Gastroenterol 112 (suppl.) : A214, 1997
 
P.288 掲載の参考文献
1) Sung JY et al : Triple therapy with sucraifate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers. Am J Gastroenterol 90 : 1424-1427, 1995
 
2) Lam SK et al : Sucralfate in Helicobacter pylori eradication strategies. Scand J Gastroenterol 30 : (suppl. 210) 59-91, 1995
 
3) Aoyama N et al : Eradication of Hericobacter pylori with modified triple therpy using sucralfate. Scand J Gastroenterol 30 : (suppl. 210) 97, 1995
 
4) Wurzer H et al : Triple therapy results with sucralfate and amoxicillin plus metronidazole in the Helicobacter pylori associated duodenal ulcer. Scand J Gastroenterol 30 : (suppl. 210) 103, 1995
 
5) Stupnicki M et al : Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating Helicobacter pylori infection. Aliment Pharmacol Ther 10 : 193-197, 1996
 
6) Korman MG et al : Sucralfate : as an alternative to bismuth in quadruple therapy fo Helicobacter pylori eradication. Helicobacter 2 : 140-143, 1997
 
7) Tachibana M et al : Comparative study on efficacy and side effects of sucralfate and lansoprazole in eradicating Helicobacter pylori when combined with metronidazole-amoxicillin dual therapy. Gastroenterology 112 : (suppl. A304), 1997
 
8) Yanaka A et al : Efficacy of sucralfate suspensions in the eradication of Helicobacter pylori. Gastroenterology 114 : G1386, 1998
 
9) Banerjee S et al : Sucralfate suppresses, Helicobacter pylori infection and reduces gastric secretion by 50% in patients with duodenal ulcer. Gastroenterology 110 : 717-724, 1996
PubMed
10) Slomiany BL et al : Supression of Helicobacter pylori urease activity by sucralfate and sulglucotide. Biochem Mol Biol Int 42 : 155-161, 1997
 
11) Slomiany BL et al : Campylobacter pylori colonization factor shows specificity for lactosylceramide sulfate and GM3 ganglioside. Biochem Int 19 : 929-936, 1989
 
12) Smoot DT et al : Effects of sucralfate on vacuolating cytotoxin activity and adherence of Helicobacter pylori tohuman gastric epithelial cells. J Associat Acad Minor. Physic 7 : 88-92, 1996
 
13) Slomiany BL et al : Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol 30 : (suppl. 210) 82-84, 1995
 
14) Higo S et al : Gastric mucoadhensive properties of the solid dispersed complex of sucralfate and tetracycline for Helicobacter pylori. Pharm Res 14 : S537-538, 1997
 
15) Slomiany BL et al : Effect of sucralfate on the degradation of human gastric mucus by Helicobacter pylori protease and lipases. Am J Gastroenterol 87 : 595-599, 1992
PubMed
16) Piotrowski J et al : Inhibition of gastric mucosal laminin receptor by, Helicobacter pylori lipopolysaccharide : Effect of sucralfate. Am J Gastroenterol 86 : 1756-1760, 1991
PubMed
17) Slomiany BL et al : Sucralfate counteracts the inhibition of gastric mucosal mucin receptor by, Helicobacter pylori lipopolysaccharide. Scand J Gastroenterol 30 : (suppl. 210) 77-81, 1995
 
P.294 掲載の参考文献
1) 会田浩幸ほか : ラット慢性潰瘍モデルにおけるZ-103の創傷治癒促進作用. 日本薬理学雑誌 99 : 345-352, 1992
Medical*Online
2) Arakawa T et al : Effects of zinc L-carnosine on gastric mucosal and cell damage caused by ethanol in rats. Correlation with endogenous prostaglandin E2. Dig Dis Sci 35 : 559-566, 1990
PubMed
3) 瀬戸孝一ほか : 亜鉛含有抗潰瘍薬ポラプレジンクの細胞増殖作用におけるIGF-1の関与. 生化学 68 : 886, 1996
 
4) Yoshikawa T et al : The antioxidant properties of a novel zinc-carnosine chelate compound, N- (3-aminopropionyl) -L-histidinato zinc. Biochim Biophys Acta 1115 : 15-22, 1991
PubMed
5) Cho CH et al : The membrane-stabilizing action of zinc carnosine (Z-103) in stress-induced gastric ulceration in rats. Life Sci 49 : PL189-194, 1991
PubMed
6) Sunairi M et al : Effects of Z-103, a new antiulcer agent, on Helicobacter pylori. -Antimicrobial, antiurease, and antiadhesive activities-. 薬理と治療 22 : 3771-3775, 1994
 
7) 北澤要ほか監修 : 胃粘膜防御因子薬の貢献の仕方, ポラプレジンク. クリニカ 24 : 210-213, 1997.
 
8) Kasahara M et al : Inhibition of the respiratory chain of Escherichia coli by zinc ions. J Biochem 72 : 777-781, 1972
PubMed
9) Anraku Y et al : Transport of sugars and amino acids in bacteria. J Biochem 78 : 149-157, 1975
PubMed
10) Reithel FJ : Ureases. In the enzymes, ed. by Boyer PD, Academic Press, New York, 1971, pp. 4 : 1-21
 
11) Noach LA et al : Mucosal necrosis factor-α, interleukin-1β and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 29 : 425-429, 1994
 
12) 吉田憲正ほか : HP時代における粘膜防御系抗潰瘍剤の意義-好中球活性化, 接着分子発現, IL-8産生の面から-. 日本消化器病学会雑誌 93 : 143, 1996.
 
13) 遠藤幹也ほか : 胃粘膜上皮細胞におけるIL-8発現のポラプレジンクによる抑制. 日本消化器病学会雑誌 95 : 215, 1998
Medical*Online
14) Yoshida N et al : Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology 105 : 1431-1440, 1993
PubMed
15) 原一郎ほか : H. Pylori抽出液刺激による好中球接着分子発現に対するZ-103の効果. 日本消化器病学会雑誌 93 : 274, 1996
 
16) Marshall BJ et al : Urea hydrolysis of patients wiht Campylobacter pyloridis infection. Lancet 1 : 965-966, 1986
 
17) Tsujii M et al : Mechanism of gastric mucosal damage induced by ammonia. Gastroenterology 102 : 1881-1888, 1992
PubMed
18) Grisham MB et al : Chlorination of endogenous amines by isolated neutrophil ; Ammonia-dependent bactericidal, cytotoxic, and cytolytic activities of the chloramines. J Biol Chem 259 : 10404-10413, 1984
PubMed
19) Kato S et al : Mucosal ulcerogenic action of monochloramine in rat stomachs ; effects of polaprezinc and sucralfate. Dig, Dis Sci 42 : 2156-2163, 1997
PubMed
20) 須川泰成ほか : 胃粘膜損傷の治癒に対するモノクロラミンの影響-ポラプレジンクおよびスクラルファートの効果-. Ther Res 19 : 121-129, 1998
 
21) Kuwayama H : Zinc compound is a novel, highly effective triple therapy for eradication of Helicobacter pylori. Gastroenterology 108 : A139, 1995
 
22) 中田博也ほか : Lansoprazole, Clarithromycin, Polaprezinc併用療法によるHelicobacter pylori除菌の効果とUrea Breath Testの有用性. Ther Res 17 : 2477-2481, 1996
Medical*Online
23) 樫村博正ほか : Helico bacter pylori陽性消化性潰瘍に対するLansoprazole, AMPC, Miconazole Gel, Polaprezincを用いた多剤併用除菌療法の検討. 新薬と臨床 46 : 52-58, 1997
 
P.299 掲載の参考文献
1) Warren JR et al : Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1 : 1273-1275, 1983
 
2) NIH Consensus Conference : Helicobacter pylori in peptic ulcer disease. JAMA 272 : 65-69, 1994
 
3) The European Helicobacter pylori Study Group : Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41 : 8-13, 1997
 
4) Proceedings of the American Digestive Health Foundation SM International Update Conference on Helicobacter pylori. supplement to Gastroenterology 113 : S1-170, 1997
 
5) Lam SK et al : Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13 : 1-12, 1998
 
6) McColm AA et al : Ranitidine bismuth citrate : anovel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture. Aliment Pharmacol Ther 10 : 241-250, 1996
 
7) Pipkin GA et al : Ranitidine bismuth citrate. Drugs of Today 33 : 431-451, 1997
 
8) Megraud F et al : Ranitidine bismuth citrate (RBC) co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 41 : A92, 1997
 
9) Lopez-Brea M et al : Synergism study of ranitidine bismuth citrate and metronidazole against metronidazole resistant. H. pylori clinical isolates. Gastroenterology 112 : A201, 1997
 
10) Kusstatscher S et al : Two different approaches after failure of standard H. pylori eradication triple therapies. Gut 41 : A98, 1997
 
11) Spadaccini A et al : Lansoprazole or ranitidine bismuth citrate based triple therapies for Helicobacter pylori eradication : Results of an open randomized study. Gut 41 : A105, 1997
PubMed
12) Kolkman JJ et al : Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. Aliment Pharmacol Ther 11 : 1123-1129, 1997
PubMed

第9章 Helicobacter pylori研究におけるピットホール

P.307 掲載の参考文献
1) 加藤元嗣ほか : Helicobacter pylori除菌と消化性潰瘍再発抑制. 消化性潰瘍治療薬のすべて, 浅香正博ほか編, 先端医学社, 東京, 1997, pp. 219-226
 
2) 消化性潰瘍再発予防研究会 : 消化性潰瘍再発予防研究会全国集計結果報告, 1995
 
3) 三好秋馬ほか : 消化性潰瘍に対する塩酸ロキサチジンアセタートの初期治療および維持療法の有用性に関する検討-アルタット研究会・全国多施設共同研究-第1報 : 総括的統計による観察成績. 臨床医薬 12 : 903-944, 1996
Medical*Online
4) Gudmand-Hoyer E et al : Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J 1 : 1095-1097, 1978
 
5) 青山伸郎ほか : 十二指腸潰瘍とH. pylori. 医学のあゆみ 186 : 519-523, 1998
Medical*Online
6) Van der Hulst RWM et al : Prevention of ulcer recurrence after eradication of Helicobacter pylori : A prospective long-term follow-up study. Gastroenterology 113 : 1082-1086, 1997
 
7) 青山伸郎 : H. pylori再発胃潰瘍の実体. H. pyloriのパラドックスをつく (第7回大雪シンポジウム), 並木正義編, 医学図書出版, 東京, 1998, pp. 61-69
 
8) Laine L et al : Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials.. Am J Gastroenterol 93 : 1409-1415, 1998
 
9) Labenz J et al : Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 : 1442-1447, 1997
PubMed
10) 浅香正博, 藤岡利生 (司会) : H. Pylori除菌後に起こる諸問題 (第84回日本消化器病学会総会パネルディスカッション抄録). 日本消化器病学会雑誌 (増刊号) 95 : 137-140, 1995
 
11) Kuipers EJ et al : atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334 : 1018-1022, 1996
 
12) Lundell L et al : Gastritis development and acid suppression therapy revisited results of a randomized clinical study with long-term follow-up. Gastroenterology (abst) 107, A771, 1997
 
13) 青山伸郎ほか : Helicobacter pylori感染と酸分泌抑制療法の問題点-PPIの感受性に対する影響ならびに粘膜萎縮の進展促進-. Helicobacter Res 3 : 258-264, 1997
Medical*Online
14) 白坂大輔 : 潰瘍治療におけるH. pylori除菌と抗潰瘍剤治療の比較. 潰瘍の本質に迫る (第8回大雪シンポジウム), 並木正義編, 医学図書出版 (近刊予定)
 
P.311 掲載の参考文献
1) Marshall B J et al : Attempt to fulfil Koch's for pyloric campylobacter. Med J Aust 142 : 436-439, 1985
 
2) Morris A et al : Ingestion of campylobacter pylori dis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 : 192-199, 1987
 
3) Langenberg W et al : Patient-to-patient transmission of Campylobacter pylori infection by fiberopic gastroduodenoscopy and biopsy. Infect Dis 161 : 507-511, 1990
 
4) Katz D et al : Erosive gastritis and acute gastrointestinal mucosal lesions. In : Progress in Gastroenterology Vol. 1, ed. by Glass GB, Grune & Stratton, New York, 1968, pp. 67-96
 
5) 渡辺英伸ほか : 病理からみたシドニーシステム. 消化器内視鏡 6 : 1019-1031, 1994
 
6) 加藤俊幸 : Helicobacter pylori感染は急性胃粘膜病変の主要な原因か. G. I. Res 3 : 542-548, 1995
Medical*Online
7) Salmeron M et al : Campylobacter like organisms and acute purulent gastritis. Lancet ii : 975-976, 1986
 
8) Frommer D J et al : Acute presentation of campylobacter pylori gastritis. Am J Gastroentrol 83 : 1168-1171, 1988
 
9) 梶田光春ほか : Helicobacter Pylori感染が関係したと考えられる小児急性胃潰瘍の1例. 日本小児栄養消化器病学会雑誌 6 : 158-162, 1992
 
10) 西元寺克禮ほか : 上部消化管内視鏡検査後に発症したAGMLの臨床的検討. Gastroenterol Endosc 31 : 785-790, 1989
 
11) Sugiyama T et al : Is Helicobacter pylori infection responsible for post endoscopic acute gastric mucosal lesions? Ezar/Gastroenterol Hepatol 4 (S. 1) : S93-S96, 1992
 
12) Dixon M F et al : Classification and grading of gastritis : The updated sydney system. Am J Surg Pathol 20 : 1161-1181, 1996
PubMed
13) Pilott A et al : Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly : a control study, Dig Dis Sci 42 : 586-591, 1997
 
14) Li E K et al : Helicobacter pylori infection increases the risk of peptic ulcer in chronic users of non-stroidal anti-inflammatory drugs, Scand J Rheumatot 25 : 42-46, 1996
 
P.316 掲載の参考文献
1) Morris A et al : Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 : 192-199, 1987
PubMed
2) Graham DY et al : Iatrogenic Camyplobacter pylori infection is a cause of epidemic achlorihydria. Am J Gastroenterol 83 : 974-980, 1988
PubMed
3) Sobala GM et al : Acute Helicbacter pylori infection : clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 32 : 1415-1418, 1991
 
4) Cave DR et al : Production of two chemically distinct acid-inhibitory factors by Helicobacter pylori. Eur J Gastroenterol Hepatol 5 (suppl. 1) : S23-7, 1993
 
5) Beil W et al : Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K+ -ATPase. Gut 35 : 1176-1180, 1994
PubMed
6) Beales IL et al : Interleukin-1β and tumor necrosis factorαinhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 42 : 227-234, 1998
 
7) Desai HG et al : Minimal dose of histamine for maximal acid secretion in control subjects and patients with duodenal ulcer. Postgrad Med J 48 : 83-86, 1972
PubMed
8) Isenberg JI et al : Increased sensitivity to stimulation of acid secretion by pentagastrin in duodenal ulcer. J Clin Invest 55 : 330-337, 1975
PubMed
9) Lam SK et al : Gastric acid secretion is abnormally sensitive to endogenous gastrin released after peptone test meals in duodenal ulcer patients. J Clin Invest 65 : 555-562, 1980
PubMed
10) El-Omar EM et al : Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109 : 681-691, 1995
PubMed
11) Gillen D et al : The acid response to gastrin distinguishes duodenal ulcer patinents from Helicobacter pylori-infected healthy subjects. Gastroenterology 114 : 50-57, 1998
 
12) Kaneko H et al : Helicobacter pylori infection induces a decrease in immunoreactive somatostatin concentrations of human stomach. Dig Dis Sci 37 : 409-416, 1992
PubMed
13) Sumii M et al : Expression of antral gastrin and somatostatin mRNA in Helicobacter pylori-infected subjects. Am J Gastroenterol 89 : 1515-1519, 1994
PubMed
14) Hanis AW et al : Eradlication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut 38 : 663-667, 1996
 
15) Labenz J et al : Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 110 : 725-732, 1996
 
16) Labenz J et al : Curing Heticobacter pylori infection in patinets with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 : 1442-1447, 1997
 
17) El-Omar EM et al : Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 : 15-24, 1997
PubMed
18) 特集/Helicobacter pyloriと酸分泌 : Helicobacter Res 1 : 217-273, 1997
 
P.323 掲載の参考文献
1) Marshall BJ : Helicobacterpylori. Am J Gastroenterol 89 : S116-128, 1994
 
2) 西川恵子ほか : Helicobacter pylori陰性消化性潰瘍の実体. Helicobacter Res 2 : 314-319, 1998
Medical*Online
3) 加藤元嗣 : Helicobacter pylori陰性消化性潰瘍の実体. Frontiers in Gastroenterology 2 : 117-124, 1996
 
4) Borody TJ et al : Helicobacter pylori-negative gastric ulcer. Am J Gastroenterol 87 : 1403-1406, 1992
PubMed
5) Borody TJ et al : Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 86 : 1154-1157, 1991
PubMed
6) Nensey YM et al : Helicobacter pylori-negative duodenal ulcer. Am J Med 91 : 151-158, 1991
 
7) McColl KE et al : A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 34 : 762-768, 1993
PubMed
8) 塩川優一ほか : 非ステロイド系抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ 31 : 96-111, 1991
 
9) Hopkins RI et al : Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence : a review. Gastroenterology 110 : 1244-1252, 1996
 
10) Van der Hulst RW et al : Prevention of ulcer recurrence after eradication of Helicobacter pylori : a prospective long-term follow-up study. Gastroenterology 113 : 1082-1086, 1997
PubMed
11) 西川恵子 : Helicobacter pylori陰性消化性潰瘍の実体. 潰瘍の本質にせまる, 並木正義編, 医学図書出版社, 東京, 1999, pp. 215-221
 
P.327 掲載の参考文献
1) Hirschl AM et al : amoxicillin for the treatment of Helicobacter pylori infection. J Gastroenterol 31 (suppl. IX) : 44-47, 1996
 
2) 小林寅吉ほか : Helicobacter pylori除菌療法による耐性菌出現の可能性は? G. I. Res 4 : 694-700, 1996
 
3) 藤岡利生 : Helicobacter pyloriをめぐって, 各種抗菌薬の特徴Current Therapy 14 : 1780-1784, 1996
 
4) Gotoh A et al : Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the ethcacy of chemotherapy. Microbiol Immunol 41 : 7-12, 1997
PubMed
5) 河合隆ほか : 薬剤感受性からみたHelicobacter Pyloriの除菌療法の検討. Progress of Digestive endoscopy 50 : 55-59, 1997
 
6) Versalovic J : Mutations in 23S rRNA are associated with clarithromicin resistance in Helicobacter pylori. Antimicrob. Agents Chemother 40 : 477-480, 1996
 
7) Taylor DE : Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother 41 : 2621-2628, 1997
PubMed
8) Szczebara F : Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori. Eur J Clin Microbiol Infect DiS 16 : 162-164, 1997
PubMed
P.332 掲載の参考文献
1) Caselli M et al : Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 44 : 101-104, 1989
PubMed
2) Graham DY et al : Long-term nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology 100 : 1653-1657, 1991
PubMed
3) Loeb DS et al : Long-term nonsteroidal anti-innammatory drug use and gastroduodenal injury : the role of Helicobacter pylori . Gastroenterology 102 : 1899-1905, 1992
 
4) Thillainayagam AV et al : Interrelationships between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and gastroduodenal disease : a prospective study in healthy volunteers. Dig DiS Sci 39 : 1085-1089, 1994
PubMed
5) Lipscomb GR et al : Influence of Helicobacter pylori on gastric mucosal adaptation to naproxen in man. Dig Dis Sci 41 : 1583-1588, 1994
 
6) Hudson N et al : Effect of Helicobacter pylori colonization on gastric mucosal eicosanoid synthesis in patients taking nonsteroidal anti-inflammatory drugs. Gect 34 : 748-751, 1993
 
7) Taha AS etα' : The interaction between Helicobacter pylori culture filtrate and indomethacin : effects on the integrity of human gastric antral mucosa and its prostaglandin E2 production in vitro. Aliment Pharmacol Ther 4 : 265-273, 1990
 
8) Quinn CM et al : Gastritis on patients on nonsteroidal anti-inflammatory drugs. Histopathology 23 : 341-348, 1993
PubMed
9) MacDonald WC : Correlation of mucosal histology and aspirin intake in chronic gastric ulcer. Gastroenterology 65 : 381-389, 1973
PubMed
10) Laine L et al : Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production : a controlled double-blind trial. Aliment Pharmacol Ther 9 : 127-135, 1995
PubMed
11) Goggin PM et al : Prevalence of Helicobacter pylori infection and its effect on symptoms and nonsteroidal antiinflammatory drug-induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 34 : 1677-1680, 1993
PubMed
12) Peterson WL et al : Relationship between Campylobacter pylori and gastritis in healthy humans after administration of placebo or indomethacin. Gastroenterology 95 : 1185-1197, 1988
PubMed
13) Shah K et al : Effect of longterrn misoprostol coadministration with nonsteroidal anti-inflammatory drugs : a histological study. Gut 37 : 195-198, 1995
PubMed
14) Laine L et al : Nonsteroidal antiinfiammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 87 : 1398-1402, 1992
 
15) Taha AS et al : Chemical gastritis and Helicobacter pylori-related gastritis in patients receiving nonsteroidal anti-inflammatory drugs : comparison and correlation with peptic ulceration. J Clin Pathol 45 : 135-139, 1992
PubMed
16) Taha AS et al : Predicting NSAID-related ulcers : assessment of clinical and pathological risk factors and importance of differences in NSAID. Gut 35 : 891-895, 1994
PubMed
17) Heresbach D et al : Helicobacter pylori : a risk and severity factor of nonsteroidal anti-inflammatory drug-induced gastropathy. Gut 33 : 1608-1611, 1992
PubMed
18) Publig W et al : Nonsteroidal anti-innammatory drugs (NSAIDs) cause gastrointestinal ulcers mainly in Helicobacter pylori carriers. Wien Min Wochenschr 106 : 276-279, 1996
 
19) Graham DY et al : Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 100 : 1653-1657, 1991
PubMed
20) Li EKM et al : Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of nonsteroidal anti-inflammatory drugs. Scand J Rheumatol 25 : 42-46, 1996
 
21) Goggin PM et al : Prevalence of Helicobacter pylori infection and its effect on symptoms and nonsteroidal anti-inflammatory drug-induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 34 : 1677-1680, 1993
PubMed
22) Kim JG et al : Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol 89 : 203-207, 1994
 
23) Schubert TT et al : Ulcer risk factors : interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med 94 : 413-418, 1993
PubMed
24) Gubbins GP et al : Helicobacter pylori seroprevalence in patients with rheumatoid. arthritis : effect of nonsteroidal and-inflammatory drugs and gold compound. Am J Med 93 : 412-418, 1992
PubMed
25) Chan FKL et al : Randomised trial of eradiaction of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet ii : 975-979, 1997
 
26) Hawkey CJ et al : Randomised controlled trial of Helicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs : HELP NSAIDs study. Lancet ii : 1016-1021, 1998
 
P.337 掲載の参考文献
1) 木村健 : 萎縮性胃炎の経年的推移. 日本消化器病学会雑誌 70 : 307-315, 1973
 
2) Sipponen P et al : The Sydney System : epidemiology and natural history of chronic gastritis. J Gastroenterol Hepatol 6 : 244-251, 1991
PubMed
3) 春間賢 : 加齢と胃炎. 胃の炎症学, 浅香正博編, メディカルレビュー社, 東京, 1997, pp. 393-409
 
4) Asaka M et al : Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging : Studies in asymptomatic Japanese adults. Helicobacter 1 : 52-56, 1996
PubMed
5) Kuipers EJ et al : Long-term sequelae of Helicobacter pylori gastritis. Lancet 345 : 1525-1528, 1995
PubMed
6) Genta RM : Helicobacter pylori, inflammation, mucosal damage, and apoptosis : pathogenesis and definition of gastric atrophy. Gastroenterology 113 : S51-S55, 1997
PubMed
7) 上村直実ほか : H. pylori感染による慢性萎縮性胃炎の進展における胃酸分泌の重要性. Ther Res 18 (suppl. 1) : 223-228, 1997
 
8) 名倉宏ほか : 慢性萎縮性胃炎の免疫学的側面. 病理と臨床 10 : 1250-1257, 1992
 
9) EL-Omar E et al : Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 : 15-24, 1997
PubMed
10) Uemura N et al : Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6 : 639-642, 1997
PubMed
11) 福田能啓 : 民族による慢性胃炎の発症・進展の差異. 消化器病セミナー 66/慢性胃炎-新しい視点-, 木村健編, へるす出版, 東京, 1997, pp. 187-194
 
P.342 掲載の参考文献
1) Cover TL et al : Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 267 : 10570-10575, 1992
PubMed
2) Atherton JC et al : Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. J Biol Chem 270 : 17771-17777, 1995
PubMed
3) Ito S et al : Profile of Helicobacter pylori cytotoxin derived from two areas of Japan with different prevalence of atrophic gastritis. Gut 39 : 800-806, 1996
PubMed
4) Azuma T et al : Contribution of HLA-DQA gene to host, s response against Helicobacter pylori. Lancet 343 : 542-543, 1994
 
5) Ota M et al : Modified PCR-RFLP method for HLA-DPB1 and-DQA1 genotyping. Tissue Antigens 38 : 60-71, 1991
PubMed
6) Tomb et al : The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 : 539-547, 1997
PubMed
P.346 掲載の参考文献
1) Graham DY et al : Iatrogenic Campylobacter pylori infection in a cause of epidemic achlorhydria. Am J Gastroenterol 83 : 974-980, 1988
 
2) Langenberg W et al : Patient-to-patient transmission of Campylobacter pylori infection by fibroptic gastrouodenoscopy and biopsy. J Infect Dis 161 : 507-511, 1990
 
3) Sugiyama T et al : Is Helicobacter pylori infection responsible for postendoscopic gastric mucosal lesions? Eur J Gastroenterol Hepatol 4 (suppl. 1) : S93-S96, 1992
 
4) Kohli Y et al : Clinical signhicance of sterilization of endoscopic instuments. Dig Endosc 6 : 33-37, 1993
 
5) 安部孝ほか : 上部消化管内視鏡検査後の急性胃粘膜病変とHelicobacter pylori. 消化器内視鏡 8 : 639-643, 1996
 
6) 中嶋睦安ほか : 内視鏡介在感染-Helicobacter pyloriを中心に-. 消化器内視鏡 3 : 1491-1494, 1991
 
7) 中嶋睦安ほか : Helicobacter pyloriの細菌学的特徴と内視鏡介在感染. 消化器内視鏡 4 : 513-518, 1992
 
8) 小寺浩ほか : 消化器内視鏡検査によるHelicobacter pylori感染と内視鏡装置の消毒法. 日本臨牀 51 : 3120-3126, 1993
Medical*Online
9) Katou M et al : Helicobacter pylori may be transmitted through gastrofiberscpe even after mannual hyamine washing. Jpn J Cancer Res 84 : 117-119, 1993
 
10) 小越和栄ほか : 消化器内視鏡機器洗浄・消毒法ガイドライン. Gastroenterol Endosc 40 : 2022-2034, 1998
 
P.350 掲載の参考文献
1) Tytgat TNJ : Remaining questions with respect to Helicobacter pylori. Gastrointest Endosc 47 : 198-199, 1998
 
2) Lee A et al : Pathogenicity of Helicobacter pylori : a perspective. Infect Immun 61 : 1601-1610, 1993
PubMed
3) Graham DY : Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer : a model. Gastroenterology 113 : 1983-1991, 1997
 
4) 水口康雄 : 常在細菌叢の分布とその影響. 戸田新細菌学 (第31版), 天児和暢ほか編, 南山堂, 東京, 1997, pp. 175-178
 
5) 光岡知足ほか : 細菌のエコロジー. 医科細菌学 (改訂第2版), 吉川昌之介編, 南江堂, 東京, 1995, pp. 231-242
 
6) Satoh K et al : A topographical relationship between, Helicobacter pylori and gastritis : quantitative assessment of Helicobacter pylori in the gastric mucosa. Am J Gastroenterol 86 : 285-291, 1991
PubMed
7) 徳丸健吉ほか : 上部消化管疾患におけるHelicobacter pylori菌株の検討. 日本消化器病学会雑誌 93 : 202, 1996
 
8) Blaser MJ : Not all Helicobacter pylori strains are created equal : should all be eliminated? Lancet 349 : 1020-1022, 1997
 
9) Graham DY : The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 350 : 70-71, 1997 (letter)
PubMed
10) Blaser MJ : The only good Helicobacter pylori is a dead Helicobacter pytori. Author's reply. Lancet 350 : 72, 1997 (letter)
 

書評

最近チェックした商品履歴

Loading...